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PERSONAL GENOMES 
Friday, September 10 – Sunday, September 12, 2010 
 
 
 
Friday 9:00 am 1  Personal Genome Landscape 
Keynote Speaker:  Eric Green 
     
Friday 1:30 pm Keynote Speaker:  Lee Hood 
   
Friday 2:30 pm 2  Poster Session I 
   
Friday 4:30 pm Wine and Cheese Party 
   
Friday 7:00 pm 3  Ethics Panel: Teaching Genomics and 
Related Ethics to Medical Professionals 
Keynote Speaker:  Henry Greely 
   
Saturday 9:00 am 4  Personal Cancer Genomes 
   
Saturday 1:30 pm 5  Poster Session II 
   
Saturday 3:00 pm 6  Personal Transcriptomes and Other 
Applications 
                        
Saturday 6:00 pm Banquet 
   
Sunday 9:00 am 7  Inherited Diseases 
   
Sunday 1:30 pm 8  Technologies for Personal Genomes 
   
 
Mealtimes at Blackford Hall are as follows:   
Breakfast   7:30 am-9:00 am 
Lunch       11:30 am-1:30 pm 
Dinner       5:30 pm-7:00 pm 
 
Bar is open from 5:00 pm until late 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstracts are the responsibility of the author(s) and publication of an 
abstract does not imply endorsement by Cold Spring Harbor Laboratory of 
the studies reported in the abstract. 
 
These abstracts should not be cited in bibliographies. Material herein 
should be treated as personal communications and should be cited as 
such only with the consent of the author. 
 
Please note that recording of oral sessions by audio, video or still 
photography is strictly prohibited except with the advance permission of 
the author(s), the organizers, and Cold Spring Harbor Laboratory. 
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PROGRAM 
 
 
FRIDAY, September 10—9:00 AM 
 
 
SESSION 1 PERSONAL GENOME LANDSCAPE 
 
Chairperson: D. Conrad, Wellcome Trust Sanger Institute, Hinxton,  
  United Kingdom 
J. Wang, Beijing Genomics Institute, Shenzhen, China 
 
 
INTRODUCTORY REMARKS 
Richard Gibbs 
 
 
KEYNOTE SPEAKER 
 
Eric D. Green 
National Human Genome Research Institute 
 
“Genomics in 2K10 and beyond—Charting a course  
for genomic medicine” 
 
 
 
 
 
1 
  
Variation in genome-wide mutation rates within and between 
human families 
Don Conrad, Jon Keebler, Mark DePristo, Sarah Lindsay, Yujun 
Zhang, Ferran Cassals, Youssef Idaghdour, Carlos Torroja, Kiran 
Garimella, Martine Zilversmit, Guy Rouleau, Mark Daly, Eric Stone, 
Matthew Hurles, Philip Awadalla. 
Presenter affiliation: Wellcome Trust Sanger Institute, Hinxton, United 
Kingdom. 
 
 
 
 
 
 
 
2 
  
Automated high-throughput analysis of personal genome 
sequences—Towards clinical interpretation 
Mark Yandell, Barry Moore, Marc Singleton, Guozhen Fan, Fidel Salas, 
Archie Russell, Edward S. Kiruluta, Martin G. Reese. 
Presenter affiliation: University of Utah School of Medicine, Salt Lake 
City, Utah. 
 
 
 
 
 
3 
 vi 
Personal genomics in a clinical setting—Experience from an 
academic medical college and children’s hospital 
Elizabeth A. Worthey, David P. Dimmock, James M. Verbsky, John T. 
Casper, Alan N. Mayer, Brennan Decker, Michael R. Tschannen, Aoy 
Tomita-Mitchell, John M. Routes, David A. Margolis, Dennis W. 
Schauer, David P. Bick, Howard J. Jacob. 
Presenter affiliation: Medical College of Wisconsin, Milwaukee, 
Wisconsin; Children's Hospital of Wisconsin, Milwaukee, Wisconsin. 
 
 
 
 
 
 
 
4 
  
Personal genomes are personalized 
Jun Wang. 
Presenter affiliation: Beijing Genomics Institute at Shenzhen, 
Shenzhen, China. 
 
 
 
5 
  
Personal genomes and phenomes—Reframing health 
Jeantine E. Lunshof. 
Presenter affiliation: Maastricht University, Maastricht, the Netherlands; 
VU University Amsterdam, Amsterdam, the Netherlands; Personal 
Genome Project, Boston, Massachusetts. 
 
 
 
 
6 
  
Refining a method for processing an individual’s whole genome 
to clinical utility 
Prasad Patil, Henk Heus, Ramy Arnaout, Peter J. Tonellato. 
Presenter affiliation: Harvard Medical School, Boston, Massachusetts. 
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FRIDAY, September 10—1:30 PM 
 
 
KEYNOTE SPEAKER 
  
Leroy E. Hood 
Institute for Systems Biology, Seattle, Washington 
 
“Systems genetics and systems biology” 
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 vii 
FRIDAY, September 10—2:30 PM 
 
 
SESSION 2 POSTER SESSION I 
 
  
The NIH Undiagnosed Diseases Program—Application of 
genome-scale sequencing to diagnostic mysteries in single 
families 
David R. Adams, Thomas C. Markello, Cynthia J. Tifft, Murat Sincan, 
Karin Fuentes Fajardo, William A. Gahl. 
Presenter affiliation: National Institutes of Health, Bethesda, Maryland. 
 
 
 
 
 
9 
  
Comparing and combining two next-generation sequencing 
technologies for human genome re-sequencing 
Sung-Min Ahn, Wooyeon Kim, Deokhoon Kim, Yongseok Lee. 
Presenter affiliation: Gachon University of Medicine and Science, 
Yeonsu-ku, South Korea. 
 
 
 
 
10 
  
The social, political, and economic impact of personal genomes 
Dan M. Bolser, Jong H. Bhak. 
Presenter affiliation: Personal Genomics Institute, Seoul, South Korea. 
 
 
11 
  
Recent advances in sequence homology assessment in the 
difference set space with application to the analysis of human 
genomes 
Andrzej K. Brodzik. 
Presenter affiliation: MITRE, Bedford, Massachusetts. 
 
 
 
 
12 
  
Differential effect of the rs4149056 variant in SLCO1B1 on 
myopathy associated with simvastatin and atorvastatin 
Liam R. Brunham, Peter Lansberg, Colin J. Ross, John J. Kastelein, 
Michael R. Hayden. 
Presenter affiliation: University of British Columbia, Vancouver, 
Canada. 
 
 
 
 
 
13 
  
Targeted sequencing identifies causal disease genes in individual 
patients with mitochondrial disease 
Sarah E. Calvo, Elena J. Tucker, Alison G. Compton, Steven 
Hershman, David R. Thorburn, Vamsi K. Mootha. 
Presenter affiliation: Broad Institute of Harvard/MIT, Cambridge, 
Massachusetts; Harvard Medical School, Boston, Massachusetts; 
Massachusetts General Hospital, Boston, Massachusetts. 
 
 
 
 
 
 
14 
  
 viii 
Improved methods for rRNA removal and mRNA-Seq library 
preparation 
Roy Sooknanan, John Hitchen, Anupama Khanna, Agnes Radek, 
Nicholas Caruccio. 
Presenter affiliation: EPICENTRE Biotechnologies, Madison, 
Wisconsin. 
 
 
 
 
 
15 
  
Medical genomics of primary immunodeficiencies 
Ferran Casals, Youssef Idaghdour, Isabel Fernández, Jonathan 
Keebler, Élie Haddad, Françoise Le Deist, Philip Awadalla. 
Presenter affiliation: Université de Montréal, Montréal, Canada. 
 
 
 
16 
  
Identification of individuals within study cohorts with unusual 
intermediate phenotypes 
Vicky E. Cho, Rohan B. Williams. 
Presenter affiliation: JCSMR, The Australian National University, 
Canberra, Australia. 
 
 
 
 
17 
  
A compilation of rare functional variations from human exomes 
Murim Choi, Weizhen Ji, Mathieu Lemaire, Clara Men, Richard P. 
Lifton. 
Presenter affiliation: Howard Hughes Medical Institute, Yale University 
School of Medicine, New Haven, Connecticut. 
 
 
 
 
18 
  
Whole-genome sequencing of autosomal recessive autism 
David W. Craig, Szabolcs Szelinger, Carpten John, Jennifer Dinh, 
Tracy Moses, Matthew Huentelman. 
Presenter affiliation: Translational Genomics Research Institute, 
Phoenix, Arizona. 
 
 
 
 
19 
  
Clinical analysis of whole genome sequence data at the Medical 
College of Wisconsin 
Brennan Decker, David P. Dimmock, David P. Bick, Howard J. Jacob, 
Elizabeth A. Worthey. 
Presenter affiliation: Medical College of Wisconsin, Milwaukee. 
 
 
 
 
20 
  
Disease progression from primary breast tumor to liver and lung 
metastases 
Nathan D. Dees, Li Ding, Robert S. Fulton, Lucinda L. Fulton, Charles 
M. Perou, Richard K. Wilson, Elaine R. Mardis. 
Presenter affiliation: Washington University School of Medicine, St. 
Louis, Missouri. 
 
 
 
 
 
21 
  
 ix 
Haplotype specific amplification in high-throughput tumor 
sequence data 
Ninad Dewal, Matthew Freedman, Thomas LaFramboise, Itsik Pe’er. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
22 
  
Multi-modal suite for disease specific analysis of next-generation 
sequencing data 
Randeep Singh, Sunil Kumar, Nevenka Dimitrova. 
Presenter affiliation: Philips Research, Briarcliff Manor, New York. 
 
 
 
23 
  
Carrier screening of recessive genetic disorders by target 
enrichment and next-generation sequencing 
Darrell L. Dinwiddie, Callum J. Bell, Neil A. Miller, Shannon L. Hateley, 
Brandon J. Rice, Stephen F. Kingsmore. 
Presenter affiliation: National Center for Genome Resources, Santa 
Fe, New Mexico. 
 
 
 
 
 
24 
  
Personal genomes and tomorrow’s doctors 
Huw R. Dorkins, Francesca Harrington. 
Presenter affiliation: University of Oxford, Oxford, United Kingdom; NW 
Thames Regional Genetics Service, Harrow, United Kingdom. 
 
 
 
25 
  
Assessment of copy-number variation in a family using both 
whole genome sequencing and array CGH 
Claudia Gonzaga-Jauregui, Jeffrey Reid, Yutao Fu, Feng Zhang, 
Pawel Stankiewicz, Quynh Doan, James R. Lupski, Richard A. Gibbs. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
 
26 
  
Whole genome low-pass sequencing combined with GWAS data 
detects variants associated with cholesterol and hemoglobin 
levels in individuals from the island of Kosrae, Micronesia 
A Gusev, M Stoffel, F M. De La Vega, J M. Friedman, J L. Breslow, I 
Pe’er. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
 
 
27 
  
Capturing the full spectrum of coding variation with de novo exon 
assembly 
Ira M. Hall, Michael R. Lindberg, Aaron J. Mackey, Aaron R. Quinlan. 
Presenter affiliation: University of Virginia, Charlottesville, Virginia. 
 
 
 
28 
  
Experiences of whole genome sequencing in the clinical 
laboratory 
Tina M. Hambuch, Marc Laurent, Brad Sickler, Arnold Liao, Mark Ross, 
David Bentley. 
Presenter affiliation: Illumina, San Diego, California. 
 
 
 
 
29 
  
 x 
Genetic basis of human sleep behaviors—Studies from familial 
sleep phase syndromes 
Angela L. Huang, Christopher R. Jones, Ying-Hui Fu, Louis J. Ptacek. 
Presenter affiliation: UCSF, San Francisco, California. 
 
 
 
30 
  
The fine-scale structure of genomic variants and its functional 
influence on gene expression 
Young Seok Ju, Jong-il Kim, Sheehyun Kim, Seungbok Lee, Hansoo 
Park, Jeong-Sun Seo. 
Presenter affiliation: Seoul National University, Seoul, South Korea; 
Macrogen Inc, Seoul, South Korea. 
 
 
 
 
 
31 
  
Somatic mutation discovery in ovarian cancer by whole genome 
and exome sequencing 
Daniel C. Koboldt, D.E. Larson, N.D. Dees, D. Shen, J. Walker, T. 
Wylie, R.T. Demeter, M. McLellan, R.S. Fulton, L. Ding, E.R. Mardis, 
R.K. Wilson. 
Presenter affiliation: Washington University in St. Louis, St. Louis, 
Missouri. 
 
 
 
 
 
 
32 
  
Enhanced method to capture the small RNA transcriptome 
Scott Kuersten, Agnes Radek, Jim Pease, Ramesh Vaidyanathan. 
Presenter affiliation: Epicentre Biotechnologies, Madison, Wisconsin. 
 
 
33 
  
Implementing 2nd generation sequencing in the clinic 
Jordan P. Lerner-Ellis, Matthew S. Lebo, Sivakumar Gowrisankar, 
Emily T. White, Lisa M. Farwell, Elizabeth Duffy, Zac L. Zwirko, 
Razvan Sultana, Arindam Bhattacharjee, Michael H. Cho, Michael F. 
Chou, Abraham M. Rosenbaum, Chad Nusbaum, Oleg Iartchouk, 
Scott T. Weiss, Victoria A. Joshi, Heidi L. Rehm, Birgit Funke. 
Presenter affiliation: Laboratory for Molecular Medicine, PCPGM, 
Cambridge, Massachusetts. 
 
 
 
 
 
 
 
34 
  
Whole exome and whole genome sequencing in the NIH 
Undiagnosed Diseases Program 
Thomas C. Markello, David A. Adams, Karin Fuentes Fajardo, Murat 
Sincan, Hannah Carlson-donohoe, Cynthia J. Tifft, Tyler M. Pierson, 
Camilo Toro, Ziegler Shira, Teer K. Jamie, Praveen F. Cherukuri, 
Nancy F. Hansen, Shankar S. Ajay, Elliot H. Margulies, Pedro Cruz, 
James C. Mullikin, William A. Gahl. 
Presenter affiliation: NIH Undiagnosed Diseases Program, Bethesda, 
Maryland. 
 
 
 
 
 
 
 
 
35 
  
 xi 
Molecular and biochemical characterization of novel syndromes 
of ketosis-prone diabetes (KPD) 
Ashok Balasubramanyam, R Nalini, Christiane S. Hampe, Diane 
Scaduto, Kerem Ozer, Ivonne Coraza, Sanjeet Patel, Dinakar Iyer, 
Lakshmi Gaur, James R. Bain, Christopher B. Newgard, Mario 
Maldonado, Michael L. Metzker. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
 
 
 
36 
  
A comparative evaluation of SNP discovery in human whole 
exome sequence data versus human whole genome sequence 
data 
Jennifer S. Parla, Ivan Iossifov, Ian Grabill, Melissa Kramer, W. 
Richard McCombie. 
Presenter affiliation: Cold Spring Harbor Laboratory, Woodbury, New 
York. 
 
 
 
 
 
 
37 
  
dbSNP and dbVar—NCBI databases of simple and structural 
variations 
Lon Phan, Ming Ward, Yu Guo-Yun, Hua Zhang, Aleksey Vinokurov, 
Mike Kholodov, Mike Feolo, David Shao, Eugene Shekhtman, Rama 
Maiti, John Lopez, John Garner, Azat Mardanov, Tim Hefferon, 
Deanna Church, Lisa Forman, Donna Maglott, Stephen Sherry. 
Presenter affiliation: NLM/NCBI, National Institutes of Health, 
Bethesda, Maryland. 
 
 
 
 
 
 
 
38 
  
The landscape of functional mutation in the human exome 
Aaron R. Quinlan, Michael Lindberg, Aaron J. Mackey, Ira M. Hall. 
Presenter affiliation: University of Virginia, Charlottesville, Virginia. 
 
 
39 
  
miRNA precursor variants and their possible effects on 
expression and function 
Jeffrey G. Reid, Yong Wang, Chun-Yu Liu, Donna Muzny, Elliot 
Gershon, Richard A. Gibbs. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
 
40 
  
CAGI—The Critical Assessment of Genome Interpretation, a 
community experiment to evaluate phenotype prediction 
S. Repo, R.K. Hart, J. Moult, S.E. Brenner. 
Presenter affiliation: University of California-Berkeley, Berkeley, 
California. 
 
 
 
 
41 
  
 xii 
An approach to clinical interpretive tools for whole genome 
sequencing 
Mark T. Ross, Tina M. Hambuch, Julianne M. O’Daniel, Lisa J. Murray, 
David R. Bentley. 
Presenter affiliation: Illumina Cambridge Ltd, Saffron Walden, United 
Kingdom. 
 
 
 
 
 
42 
  
The ARRA autism sequencing collaboration, Phase 1—Deep 
whole exome sequencing in 1000 autism cases and 1000 matched 
controls 
Aniko Sabo, Christine Stevens, Benjamin Neale, Donna Muzny, Uma 
Nagaswamy, Irene Newsham, Jeffrey Reid, Stacey Gabriel, Mark Daly, 
Joseph Buxbaum, Bernie Devlin, Gerard Schellenberg, James 
Sutcliffe, Richard Gibbs. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
 
 
 
 
43 
  
Managing genome databases with UTGB Toolkit 
Taro L. Saito, Jun Yoshimura, Hiroshi Minoshima, Wei Qu, Shinichi 
Morishita. 
Presenter affiliation: University of Tokyo, Chiba, Japan. 
 
 
 
44 
  
Transcriptome profiling of cardiovascular disease by massively 
parallel short-read DNA sequencing 
Shurjo K. Sen, Praveen F. Cherukuri, Jennifer J. Barb, Peter J. 
Munson, Jamie K. Teer, Abdel G. Elkahloun, Shih-Queen Lee-Lin, Eric 
D. Green, Leslie G. Biesecker, James C. Mullikin. 
Presenter affiliation: National Institutes of Health, Bethesda, Maryland. 
 
 
 
 
 
45 
  
Massively parallel screening of genetic alterations in common 
cancers 
Rizza Padilla, Anjali B. Shah, Lin Z. Pham, Yongming Sun, Jingwei Ni, 
Marta Matvienko, Nicole Hoag, Janet Ziegle. 
Presenter affiliation: Life Technologies, Foster City, California. 
 
 
 
 
46 
  
Telomere analysis using next-gen sequence data 
Nicholas Stong, Ravi Gupta, Ramana Davuluri, Harold Riethman. 
Presenter affiliation: Wistar Institute, Philadelphia, Pennsylvania; 
University of Pennsylvania, Philadelphia, Pennsylvania. 
 
 
 
47 
  
The application of genome-wide association studies of aging in a 
patient-driven clinical trial 
Melanie Swan, Aaron Vollrath, Raymond McCauley. 
Presenter affiliation: DIYgenomics, Palo Alto, California. 
 
 
 
48 
  
 xiii 
Whole-genome sequencing of a family of four—Educational and 
ethical perspectives 
John S. West. 
Presenter affiliation: ViaCyte, Inc., San Diego, California. 
 
 
 
49 
  
The emerging role of core sequencing facilities in the personal 
genomes era 
Lisa D. White, Alina Raza, Mylinh Hoang, Carl Broadbent, Laura A. 
Liles, Yanglong Mou. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
 
50 
  
Exploiting a hierarchical clustering tree of gene-expression traits 
in eQTL analysis 
Seyoung Kim, Eric P. Xing. 
Presenter affiliation: Carnegie Mellon University, Pittsburgh, 
Pennsylvania. 
 
 
 
 
51 
  
Leveraging genetic interaction networks for joint mapping of 
marginal and epistatic eQTLs 
Seunghak Lee, Seyoung Kim, Eric P. Xing. 
Presenter affiliation: Carnegie Mellon University, Pittsburgh, 
Pennsylvania. 
 
 
 
 
52 
  
MoGUL—Detecting common insertions and deletions in a 
population 
Seunghak Lee, Eric P. Xing, Michael Brudno. 
Presenter affiliation: Carnegie Mellon University, Pittsburgh, 
Pennsylvania; University of Toronto, Toronto, ON, Canada. 
 
 
 
 
53 
  
Using genetic information in risk prediction for alcohol 
dependence in the Collaborative Study on the Genetics of 
Alcoholism GWAS sample 
Jia Yan, Fazil Aliev, Vernell S. Williamson, Bradley T. Webb, Alison M. 
Goate, John R. Kramer, John I. Nurnberger Jr, Marc A. Schuckit, Jay 
A. Tischfield, John M. Quillin, Danielle M. Dick. 
Presenter affiliation: Virginia Commonwealth University, Richmond, 
Virginia. 
 
 
 
 
 
 
 
54 
  
Low coverage personal genomics enabled by an integrative SNP 
pipeline 
Yi Wang, Jin Yu, Richard A. Gibbs, Fuli Yu. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
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 xiv 
FRIDAY, September 10—4:30 PM 
 
Wine and Cheese Party 
 
 
FRIDAY, September 10—7:00 PM 
 
 
SESSION 3 ETHICS PANEL: TEACHING GENOMICS AND RELATED  
  ETHICS TO MEDICAL PROFESSONALS 
 
 
KEYNOTE SPEAKER 
  
Henry Greely 
Stanford University, Stanford, California 
 
“Preparing for the coming tsunami of clinical genomic information” 
 
 
 
56 
 
 
PANEL MEMBERS 
  
Ethical, social, moral, and legal issues arising from chromosomal 
microarray analysis 
Arthur L. Beaudet. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
57 
  
The pathologist’s post-genome practice 
Mark S. Boguski, Ramy Arnaout, Richard L. Haspel, Lauren Briere, 
Karen Marchand, James Connolly, Sibel Kantarci, Jeffrey E. Saffitz, 
Peter J. Tonellato. 
Presenter affiliation: Beth Israel Deaconess Medical Center, Boston, 
Massachusetts. 
 
 
 
 
 
58 
  
Ethical considerations of comprehensive genomic analysis in 
clinical practice and research 
Wendy K. Chung. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
59 
  
Julianne O’Daniel. 
Presenter affiliation: Illumina Inc., Chapel Hill, North Carolina. 
 
  
Initial results from DNA sequencing of a family of four 
Anne V. West. 
Presenter affiliation: The Harker School, San Jose, California. 
 
 
60 
 
 xv 
SATURDAY, September 11—9:00 AM 
 
 
SESSION 4 PERSONAL CANCER GENOMES 
 
Chairperson: S. Grimmond, University of Queensland, St. Lucia,  
  Australia 
S. Jones, BC Cancer Agency, Vancouver, Canada 
 
  
Studying pancreatic cancer at single nucleotide resolution 
N. Waddell, K. Kassahn, B. Gardiner, N. Cloonan, G. Kolle, J.V. 
Pearson, A. Biankin, S.M. Grimmond. 
Presenter affiliation: University of Queensland, Brisbane, Australia. 
 
 
 
61 
  
Genome evaluation, functional studies, and research translation 
in renal cell carcinoma 
Samuel Pena Llopis, Toshinari Yamasaki, Brad Sickler, Arnold Liao, 
Sharanya Sivanand, Blanka Kucejova, Wareef Kabbani, Tina 
Hambuch, Suneer Jain, Tram Tran, Pia Banerji, Noelle Williams, Marc 
Laurent, Mark Ross, David Bentley, James Brugarolas. 
Presenter affiliation: UT Southwestern Medical Center, Dallas, Texas. 
 
 
 
 
 
 
62 
  
Whole genome sequencing, analysis and diagnosis of a patient 
with acute promyelocytic leukemia (APL) 
Elaine R. Mardis, Li Ding, Ken Chen, John Wallis, John Welch, Joelle 
Viezer, Michael D. McLellan, Tammy Vickery, Jerry Reed, Daniel 
Koboldt, Sashi Kulkarni, Richard K. Wilson, Timothy J. Ley, Peter 
Westervelt. 
Presenter affiliation: Washington University School of Medicine, St. 
Louis, Missouri. 
 
 
 
 
 
 
 
63 
  
Clinical utility of genomic sequencing of a rare adenocarcinoma 
Steven J. Jones, Janessa Laskin, Yvonne Y. Li, Obi L. Griffith, Yaron 
S. Butterfield, Jefferson Terry, Richard Corbett, Nataliya Melnyk, 
Montgomery Martin, Sohrab P. Shah, Margaret Sutcliffe, Yongjun 
Zhao, Richard A. Moore, David G. Huntsman, Inanc Birol, Martin Hirst, 
Robert A. Holt, Marco A. Marra. 
Presenter affiliation: BC Cancer Agency, Vancouver, Canada. 
 
 
 
 
 
 
64 
  
IntOGen, Integrative OncoGenomics for personal cancer 
genomes 
Christian Pérez-Llamas, Gunes Gundem, Núria López-Bigas. 
Presenter affiliation: Pompeu Fabra University, Barcelona, Spain. 
 
 
 
65 
  
 xvi 
Screening for germline variants that predispose to cancer from 
next-generation sequencing data 
Lisa R. Trevino, David A. Wheeler, Kyle Chang, Nipun Kakkar, Jeffrey 
G. Reid, Donna M. Muzny, Richard A. Gibbs. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
 
66 
 
 
SATURDAY, September 11—1:30 PM 
 
 
SESSION 5 POSTER SESSION II 
 
See Poster Session I for list of posters. 
 
 
 
SATURDAY, September 11—3:00 PM 
 
 
SESSION 6 PERSONAL TRANSCRIPTOMES AND OTHER 
APPLICATIONS 
 
Chairperson: P. Laird, University of Southern California, Los Angeles 
R. Myers, HudsonAlpha Institute for Biotechnology,  
Huntsville, Alabama 
 
  
Mining the cancer methylome 
Peter W. Laird. 
Presenter affiliation: University of Southern California, Los Angeles, 
California. 
 
 
 
67 
  
Post-transcriptional modification of microRNAs is a common, 
conserved mechanism that increases complexity in the microRNA 
transcriptome 
Stacia K. Wyman, Emily C. Knouf, Rachael K. Parkin, Muneesh 
Tewari. 
Presenter affiliation: Fred Hutchinson Cancer Research Center, 
Seattle, Washington. 
 
 
 
 
 
 
68 
  
Correlating genotyping and gene expression data with next-
generation whole genome sequencing data 
Randeep Singh, Sina Vivekanandan, Sunil Kumar, Melissa Kramer, 
Laura Gelley, Elena Ghiban, Sithartan Kamalakaran, Vinay Varadan, 
Richard McCombie, Nevenka Dimitrova. 
Presenter affiliation: Philips Research, Briarcliff Manor, New York. 
 
 
 
 
 
69 
 xvii 
Personal functional genomics 
Richard M. Myers, Timothy E. Reddy, Jason Gertz, Florencia Pauli, 
Katherine E. Varley, Barbara Wold. 
Presenter affiliation: HudsonAlpha Institute for Biotechnology, 
Hunstville, Alabama. 
 
 
 
 
70 
  
A comparison of two methods for digitally quantifying mRNAs 
Phil Chapman, Linda Harndahl, Claire Dunkley, Alison Davies, Henry 
Brown, Anna Marley, Magnus Ulvsback, Ulrika Edvardsson, Ellen 
Brown, Sarah Runswick, Caroline Hellawell, Hedley Carr, Neil Gibson. 
Presenter affiliation: AstraZeneca Pharmaceuticals, Macclesfield, 
United Kingdom. 
 
 
 
 
 
71 
  
Allele-specific DNA methylation in a three-generation family 
reveals genetic influence on epigenetic regulation 
Katherine E. Varley, Jason Gertz, Timothy E. Reddy, Kevin M. 
Bowling, Florencia Pauli, Stephanie L. Parker, Katerina S. Kucera, 
Huntington F. Willard, Richard M. Myers. 
Presenter affiliation: HudsonAlpha Institute for Biotechnology, 
Huntsville, Alabama. 
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SATURDAY, September 11 
 
BANQUET 
 
Cocktails  6:00 PM Dinner  6:45 PM 
 
 
SUNDAY, September 12—9:00 AM 
 
 
SESSION 7 INHERITED DISEASES 
 
Chairperson: L. Jorde, University of Utah School of Medicine,  
Salt Lake City 
D. Altshuler, Broad Institute, Cambridge, Massachusetts 
 
  
Direct estimates of the human mutation rate using whole-genome 
sequence data 
Jared C. Roach, Gustavo Glusman, Arian F. Smit, Chad D. Huff, 
Robert Hubley, Paul T. Shannon, Lee Rowen, Krishna P. Pant, Nathan 
Goodman, Michael Bamshad, Jay Shendure, Raoje Drmanac, Lynn B. 
Jorde, Leroy Hood, David J. Galas. 
Presenter affiliation: University of Utah, Salt Lake City, Utah. 
 
 
 
 
 
 
73 
 xviii 
Rick Lifton. 
Presenter affiliation:  Yale University School of Medicine, New Haven, 
Connecticut. 
 
  
Mutation discovery for autosomal dominant diseases 
Matthew Bainbridge, Dustin Baldridge, Donna Muzny, Brendan Lee, 
John L. Jefferies, Richard Gibbs. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
74 
  
David Altshuler. 
Presenter affiliation:  Broad Institute, Cambridge, Massachusetts. 
 
  
Whole genome sequence of a Crohn disease trio—A paradigm for 
complex disease etiology discovery 
Philip Rosenstiel, Andre Franke, Bjorn Stade, Mathias Barann, 
Clarence Lee, Annette Fritscher-Ravens, Kevin McKernan, Stefan 
Schreiber. 
Presenter affiliation: University Kiel, Kiel, Germany. 
 
 
 
 
 
75 
  
Comparison and application of whole exome and genome 
sequencing on an individual with high risk for atherosclerosis 
Jamie K. Teer, Nancy F. Hansen, Praveen F. Cherukuri, Lori L. 
Bonnycastle, Pedro Cruz, Peter S. Chines, Hatice Ozel Abaan, Elliott 
H. Margulies, Eric D. Green, James C. Mullikin, Leslie G. Biesecker. 
Presenter affiliation: NHGRI, National Institutes of Health, Bethesda, 
Maryland. 
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SUNDAY, September 12—1:30 PM 
 
 
SESSION 8 TECHNOLOGIES FOR PERSONAL GENOMES 
 
Chairperson: G. Church, Harvard Medical School, Boston, Massachusetts 
 
  
PostLight sequencing with semiconductor chips 
Jonathan M. Rothberg. 
Presenter affiliation: Ion Torrent, Guilford, Connecticut. 
 
 
77 
  
Single molecule real-time DNA sequencing on the surface of a 
quantum-dot nanocrystal 
Joseph M. Beechem. 
Presenter affiliation: Life Technologies, Carlsbad, California. 
 
 
 
78 
  
 xix 
Algorithms for resequencing and assembly using strobe 
sequencing data 
Anna Ritz, Ali Bashir, Benjamin J. Raphael. 
Presenter affiliation: Brown University, Providence, Rhode Island. 
 
 
 
79 
  
Zhemin Zhang. 
Presenter affiliation: Genentech Inc., South San Francisco, California. 
 
  
Enabling a more comprehensive understanding of your risk of 
infection from viral pathogens via the construction of a real-time 
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 1 
GENOMICS IN 2K10 AND BEYOND: CHARTING A COURSE FOR 
GENOMIC MEDICINE 
 
Eric D Green  
 
National Human Genome Research Institute, National Institutes of Health, 
Bethesda, MD, 20892 
 
The Human Genome Project’s completion of the human genome sequence 
in 2003 was a landmark scientific achievement of historic significance. It 
also signified a critical transition for the field of genomics, as the new 
foundation of genomic knowledge began to be used in powerful ways by 
researchers and clinicians to tackle increasingly complex problems in 
biomedicine. To exploit the opportunities provided by the human genome 
sequence and to ensure the productive growth of genomics as one of the 
most vital biomedical disciplines of the 21st century, the National Human 
Genome Research Institute (NHGRI) is crafting and pursuing a broad vision 
for genomics research that includes facilitating and supporting the highest-
priority research areas that will help to usher in the era of genomic 
medicine. 
 2 
VARIATION IN GENOME-WIDE MUTATION RATES WITHIN AND 
BETWEEN HUMAN FAMILIES 
 
Don Conrad1, Jon Keebler2, Mark DePristo3, Sarah Lindsay1, Yujun Zhang1, 
Ferran Cassals4, Youssef Idaghdour4, Carlos Torroja4, Kiran Garimella3, 
Martine Zilversmit4, Guy Rouleau4, Mark Daly3, Eric Stone5, Matthew 
Hurles1, Philip Awadalla4, 1000 Genomes Project1  
 
1Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, United Kingdom, 
2North Carolina State University, Dept. of Genetics, Raleigh, NC, 27659, 
3The Broad Institute of Harvard and MIT, Program in Medical and 
Population Genetics, Cambridge, MA, 02142, 4University of Montreal, Ste 
Justine Hospital Research Centre, Department of Pediatric, Faculty of 
Medicine, Montreal, H3T 1C5, Canada, 5North Carolina State University, 
Bioinformatics Research, Raleigh, NC, 27695 
 
Cost-efficient whole genome resequencing now enables the identification of 
de novo mutations (DNMs) genome-wide in multiple families. Here we 
present the first comparative analysis of male and female germline mutation 
rates in two deeply sequenced parent-offspring trios. We validated nearly 
6,000 potential DNMs, identifying among these 1,586 non-germline 
mutations arising either somatically or in the cell-line, as well as 49 and 35 
germline DNMs in the two trio offspring, consistent with mutation rates of 
1.4 x 10-8 and 1.0 x 10-8 per base per generation, respectively. Most 
strikingly, in one family we observed that ~90% of DNMs came from the 
paternal germline, while, in complete contrast, in the other family ~60% of 
DNMs came from the maternal germline. These observations can only be 
explained by extensive variation in the male and female germline mutation 
rates in the two families. As an early glimpse into the coming wave of 
somatic cell sequencing, we also used the large collection of validated non-
germline DNMs to study the mutation processes operating in 
(immortalized) B cells; these variants show the signature of transcription-
coupled repair and have a primary sequence context quite different from 
common germline polymorphism. We examined the implications of our 
results for personal genomics efforts that are currently underway, by 
estimating the number and putative functional impact of novel variants that 
we expect to see in a typical newborn genome. In total, our findings add 
confidence to current DNM rate estimates, unveil unexpected, sex-linked 
rate variation, and suggest caution when interpreting rare variation 
discovered with next-generation DNA sequencing for human evolutionary 
and disease studies. 
 3 
AUTOMATED HIGH-THROUGHPUT ANALYSIS OF PERSONAL 
GENOME SEQUENCES: TOWARDS CLINICAL INTERPRETATION 
 
Mark Yandell1, Barry Moore1, Marc Singleton1, Guozhen Fan1, Fidel 
Salas2, Archie Russell2, Edward S Kiruluta2, Martin G Reese2  
 
1University of Utah & School of Medicine, Human Genetics, Salt Lake 
City, UT, 84112, 2Omicia Inc., 2200, Emeryville, CA, 94608 
 
As recent publications have made clear, manual analysis of personal 
genome sequences is a massive, labor-intensive task1. Although much 
progress is being made in read alignment and variant calling, little software 
yet exists for the automated analysis of personal genome sequences. Indeed, 
the ability to automatically annotate variants, to combine data from multiple 
projects, and to recover subsets of annotated variants for diverse 
downstream analyses is becoming a critical analysis bottleneck. Here we 
present an automated and integrated analysis of more than 20 personal 
genome sequences, including the previously analyzed and published 10Gen 
dataset in GVF format 
(http://www.sequenceontology.org/resources/10Gen.html), using a newly 
developed tool called VAAST, the Variant Annotation, Analysis and 
Selection Tool. VAAST provides simple means to: 1) combine and compare 
whole genome variant data for diverse downstream analyses; (2) identify 
hotspots of variation within a genome and its annotations, e.g. genes, 
regulatory elements, etc; and (3) perform ontology-driven analyses in order 
to investigate variation within a given GO category, disease class or 
metabolic pathway. Importantly, these analyses can be carried out on sets of 
genomes, making possible both pairwise and case-control style studies of 
personal genome sequences. We present here several analyses of healthy 
and cancer genomes and show how VAAST can be used to identify 
variation hotspots both along the chromosome, and within gene ontologies, 
disease classes and metabolic pathways. Special emphasis is placed upon 
the impact of data quality and ethnicity, and their consequences for further 
downstream analyses. We also show how variant calling procedures, 
pseudogenes and gene families all combine to complicate clinically-
orientated analyses of personal genome sequences in ways that only become 
apparent when cohorts of genomes are analyzed. 
 
1 Ashley, EA et al. “Clinical Assessment incorporating a personal genome”, 
Lancet, 375(9725): 1497-8, 2010. 
 4 
PERSONAL GENOMICS IN A CLINICAL SETTING: EXPERIENCE 
FROM AN ACADEMIC MEDICAL COLLEGE AND CHILDREN’S 
HOSPITAL  
 
Elizabeth A Worthey1,2,3,4, David P Dimmock1,2,4, James M Verbsky1,2,4, 
John T Casper1,2,4, Alan N Mayer1,2,4, Brennan Decker1,2,4, Michael R 
Tschannen1, Aoy Tomita-Mitchell1,2,4, John M Routes2,4, David A 
Margolis2, Dennis W Schauer2,4, David P Bick1,2,4, Howard J Jacob1,2,3,4  
 
1Medical College of Wisconsin, The Human and Molecular Genetics 
Center, Milwaukee, WI, 53226, 2Medical College of Wisconsin, Pediatrics, 
Milwaukee, WI, 53226, 3Medical College of Wisconsin, Physiology, 
Milwaukee, WI, 53226, 4Children's Hospital of Wisconsin, Children's 
Research Institute, Milwaukee, WI, 53226 
 
Unbiased screening for causative mutations using genomic sequencing has 
been suggested as one plausible route to a diagnosis when a patient's 
phenotype does not suggest a known defect. Over the last year, a number of 
publications have reported the use of exome sequencing in human patient. 
Additional studies have made use of whole genome sequencing in a clinical 
context. At the Medical College of Wisconsin (MCW) and the Children’s 
Hospital of Wisconsin (CHW), we are using whole exome and whole 
genome sequencing to identify disease associated variations in children with 
life-threatening, but undefined disease.  
 
Here we report on a number of these studies. We discuss not only the 
findings from three cases and the current state of clinical genome 
sequencing at MCW/CHW, but also: the main steps involved in annotation 
of the large numbers of variants derived from these sequencing strategies, 
the methodology and tools developed to provide the geneticist with the 
means of prioritising these variants as required for interpretation of the data 
in light of the patient’s clinical presentation and family history, and the 
challenges, and solutions faced, and developed during these studies.  
 5 
PERSONAL GENOMES ARE PERSONALIZED. 
 
Jun Wang  
 
BGI-Shenzhen, Department of Bioinformatics, Shenzhen, 518083, China 
 
It is ten years since human genome project was drafted, yet we are still 
asking how genomes will help health care for general people. Recent 
sequencing revolution have brought affordable personal genomes into 
practice in terms of cost and throughput, but it remains very difficult to 
interpret a genome to make sense for the owner. Scientists are still 
struggling in biomedical genomics studies to get the meaning of every 
nucleotide in the sequence, while missing heritability in complex diseases 
confused researchers, and prevented disease modeling, prevention and 
precaution. Our recent studies have proposed two possible explanations to 
the missing heritability. First, we have discovered an excess of rare, 
deleterious SNPs in average human population, which are not designed in 
current genome-wide association study (GWAS) arrays. Second, we 
identified extensive structural variations as well as individual-specific 
sequences among human individuals with potential functional impacts. In 
all, we believe each human genome is actually highly personalized, or 
private, as a personal genome. The continuous innovations in the 
technology would finally prove that by complete de novo assembly of 
multiple private genomes could we find the key to human genomics for 
medical genomics and health care.  
 6 
PERSONAL GENOMES AND PHENOMES: REFRAMING HEALTH 
 
Jeantine E Lunshof1,2,3  
 
1Maastricht University, Institute for Public Health Genomics, Maastricht, 
6226ES, Netherlands, 2VU University Amsterdam, Dept. of Molecular Cell 
Physiology, Amsterdam, 1081HV, Netherlands, 3Personal Genome Project, 
Genetics Department, Harvard Medical School, Boston, MA, 02115 
 
The increasing availability of personal genome sequence information, 
enabled by advances in technology, combined with comprehensive 
phenome data puts the human organism under a new microscope. What we 
see there, may change our traditional concepts of health and disease. Even if 
computational work towards data interpretation is only at the beginning, 
biological insights at the molecular level already lead to a blurring of the 
boundaries of what we regard as states of health and disease. Integrating 
knowledge from the genome, the phenome and the envirome at all levels – 
molecules, cells, organism – results in a landscape1 of complexity instead of 
a clear picture of individual health or disease. New patterns emerge from 
the systems biology-guided interpretation of the amassed data sets and this 
already influences nosology: we need to revise our classification of 
diseases. The impact of this reaches far beyond biology. I will argue that a 
reframing of ‘health’ has consequences for the normative structures that 
have been built upon it. For example, the way we delineate ‘health’ (and 
thereby: ‘disease’) determines what we call ‘diagnostic’, ‘therapeutic’, 
‘medical’. The increasing and broad availability of personal genome 
information magnifies the untenability of these concepts. The practical, 
daily life consequences of a reframing of ‘health’ may be profound. In 
short: will a biology-based reframing of ‘health’ force us to revise parts of 
our ethical and legal reasoning?  
 
 
1Kohl P, et al..Clin Pharmacol Ther. June 2010. doi:10.1038/clpt.2010.92 
 7 
REFINING A METHOD FOR PROCESSING AN INDIVIDUAL’S 
WHOLE GENOME TO CLINICAL UTILITY 
 
Prasad Patil1, Henk Heus2, Ramy Arnaout3, Peter J Tonellato1,3  
 
1Harvard Medical School, Center for Biomedical Informatics, Boston, MA, 
02115, 2GenomeQuest, Inc., Westborough, MA, 01581, 3Beth Israel Deaconess 
Medical Hospital, Department of Pathology, Boston, MA, 02115 
 
The use of whole genome sequencing data will profoundly change health care. 
Before this complex data is adapted to routine best practice, several technical 
and procedural barriers must be resolved. To address these barriers, we 
developed an automated, open-source, modular pipeline that detects, annotates, 
and reports variants in individual whole genome assemblies using a standard, 
quality-driven format. We analyze the results of processing 4 whole genome 
data sets and test against a commercial pipeline for validation. 
 
We use MAQ as an example alignment and variant detection tool1. BioPerl 
scripts pre-process input and post-process output files into annotated variants 
using HGVS nomenclature and gene, quality, and clinical information. Diverse 
input formats can be used and standardized output formats provide a simple 
platform for tailoring to EMR input specifications. Results are compared against 
a commercially-available GenomeQuest (GQ) NGS mapping system. 
 
We process four genomes (African, Caucasian, Chinese, and Watson) using 
input formats including NGS, FASTQ and private variant files. As an example, 
analysis of the 4 billion NGS reads for the African genome2 produced 4.2 
million SNPs with a 72.4% overlap with dbSNP (compared to 73.8% by the 
original assembly2). Of these SNPs, >500,000 appear in gene regions. Post-
processing provides annotated variants then used for clinical assessments, such 
as using a model3 to predict warfarin dose. We compare the mapping, variant 
call, and annotation with the GQ system’s results and identify analysis 
components that require refinement to improve clinical accuracy of the systems 
and clarify the EMR integration points. Our analysis contributes to a cost-
benefit analysis to define the reimbursement model that will drive use of whole 
genome data in health care. 
 
Our pipeline is designed to reduce an individual whole genome into clinically-
relevant, quality-driven data suitable for incorporation into the EHR. This 
examination of the automated mapping and clinical annotation of an 
individual’s entire genome is instrumental when engineering the integration of 
personal genomic medicine into best practice medicine. 
 
References 
1. Li et. al. Mapping short DNA sequencing reads and calling variants using mapping quality 
scores. Genome Res. 2008;18:1851-1858. 
2. Bentley et. al. Accurate whole human genome sequencing using reversible terminator 
chemistry. Nature. 2008;456:53-59. 
3. Gage et. al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of 
warfarin. Clin.Pharmacol.Ther. 2008;84(3):326-331. 
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SYSTEMS GENETICS AND SYSTEMS BIOLOGY 
 
Leroy E Hood  
 
Institute for Systems Biology, Executive/Science, Seattle, WA, 98103 
 
Systems approaches to genetics and medicine encompass the idea of a 
holistic as opposed to an atomistic approach to biological complexity—be it 
genetics or medicine. I will discuss the 21st century challenge for science 
and engineering—complexity—and suggest we can deal most effectively 
with this complexity through a systems approach employing molecular and 
phenotypic data (much arising from emerging high throughput 
technologies) as well as powerful new computational and mathematical 
tools for analyzing, integrating and modeling these data. This approach 
leads to the concept that biology is an informational science. I will discuss 
these systems approaches to genetics and medicine citing several examples 
that we have recently analyzed.  
 
First, I will discuss the whole genome sequence analyses that we have 
performed on a family of four exhibiting two simple Mendelian diseases. 
These analyses allowed us to 1) determine that the principles of Mendelian 
genetics can be used to identify about 70% of the sequencing errors—thus 
producing highly accurate genomics sequence data, 2) create a relative 
complete recombinational map for individual members of the family 
(demonstrating hot spots of recombination), 3) identify directly about 
240,000 rare mutant alleles, 4) determine the intergenerational mutation rate 
for the family, and 5) employ simple models to identify just four disease 
gene candidates for the two genetic diseases. These studies illustrate the 
power of having complete genome sequences to execute family systems 
genetic analyses. I will then discuss how we plan to approach the systems 
analyses of more complex genetic diseases with new approaches to 
phenotyping and complete family genome sequence analyses.  
 
Second, I will discuss our recent studies on a systems approach to prion 
disease employing the integration of five different types of data to create 
powerful predictive models—and the challenge of signal to noise issues in 
all high throughput data sets. These data have striking implications for new 
approaches to diagnostics and therapy.  
 
The systems approach to disease, the new dimensions of exploration of 
patient data space arising from emerging high throughput technologies and 
the development of new computational and informational techniques 
suggest that over the next 10 years medicine will be transformed from its 
current reactive mode to a proactive mode that is predictive, personalized, 
preventive and participatory (P4 medicine). I will discuss briefly the 
medical and societal implications of P4 medicine.  
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THE NIH UNDIAGNOSED DISEASES PROGRAM: APPLICATION OF 
GENOME-SCALE SEQUENCING TO DIAGNOSTIC MYSTERIES IN 
SINGLE FAMILIES. 
 
David R Adams, Thomas C Markello, Cynthia J Tifft, Murat Sincan, Karin 
Fuentes Fajardo, Gahl A William  
 
National Institutes of Health, Undiagnosed Diseases Program, Bethesda, 
MD, 20892 
 
The NIH Undiagnosed Diseases Program (UDP) is a pilot program 
designed to address the needs of persons with debilitating medical 
conditions for which no diagnosis has been found despite an extensive 
workup. The goals of the UDP include finding accurate diagnoses and 
discovering new diseases that provide insight into human physiology and 
genetics. To date, 3000 inquiries have been received, 1192 medical records 
have been reviewed, 227 people have been accepted to the program and 84 
have been referred to other ongoing studies. So far, 160 accepted 
individuals have been brought to the NIH for in-depth medical evaluation. 
Approximately 15% of evaluated individuals have received a specific 
diagnosis and an additional number have generated strong candidates for 
research follow-up. Most applicants have multisystem disease, often 
including a predominant neurological component. Diagnoses have been 
made before, during and after admission to the NIH clinical center. 
Diagnoses based on clinical evaluation and testing include amyloidosis, 
Smith-Magenis syndrome and hereditary spastic paraplegia. Diagnoses 
based on research testing include spinocerebellar ataxia type 28, congenital 
disorder of glycosylation IIb, and a novel arterial calcification syndrome. 
Research molecular analysis includes SNP array screening for indels, 
contiguous homozygosity, uniparental disomy, consanguinity, and 
crossover-delineated linked regions, and whole exome/genome sequencing. 
Whole exome data has been collected for eight families, and has already 
yielded an experimentally-verified, disease-causing mutation in one family. 
Whole-genome and whole-exome sequencing of additional families is 
underway. Interim analysis is being used to refine our diagnostic 
methodology. For example, few diseases appear to be uncommon 
presentations of known conditions, and extensive clinical-hypothesis-driven 
Sanger sequencing has yielded few useful results. We have also defined a 
set of rules for determining which family members’ DNA should be 
obtained to maximize the use of genetic models to filter variants generated 
by whole exome analysis. Future development of the NIH UDP pilot will 
include expansion of in-house research and collaboration to follow-up the 
abundant basic research leads arising from UDP cases. 
 10 
COMPARING AND COMBINING TWO NEXT-GENERATION 
SEQUENCING TECHNOLOGIES FOR HUMAN GENOME RE-
SEQUENCING 
 
Sung-Min Ahn1, Wooyeon Kim2, Deokhoon Kim1, Yongseok Lee2  
 
1Gachon University of Medicine and Science, Lee Gil Ya Cancer and 
Diabetes Institute, Yeonsu-ku, 403-860, South Korea, 2Samsung SDS, 
Bioinformatics, Bundang-ku, 463-870, South Korea 
 
The next-generation sequencing (NGS) technology has enabled personal 
genomics by reducing sequencing cost and increasing its efficiency, yet 
there remain challenges in current-re-sequencing strategy such as different 
outputs depending on sequencing platforms and algorithms as well as 
technical limitations for detecting structural variations (SVs) and for 
phasing. Therefore, a rigorous comparison of different sequencing methods 
is needed while an optimal combination of technologies and platforms for 
optimal coverage and accuracy of genome re-sequencing needs to be 
determined. In this study, we re-sequenced SJK genome, the first Korean 
genome sequenced using Illumina's polymerase-based GA II platform, 
using ABI's ligase-based SOLiD platform. In total, 106.28 Gb from mate-
paired libraries with average insert sizes of 1-2kb , representing an average 
sequencing depth of 34X, were aligned onto the NCBI human reference 
genome to 98.20% coverage. We identified 3.4 million single nucleotide 
polymorphisms (SNPs) using ABI's SOLiD platform, 86% of which were 
shared with our previous results using Illumina's GA II platform. In the 
meanwhile, 338,456 and 384,605 SNPs were independently detected in 
SOLiD and GAII platforms, respectively. As for small indels ranging from -
29 to +14 bp, only 56% of 271,847 indels identified using SOLiD platform 
were shared with the results using GA II platform. In addition, using mate-
paired reads, we identified 177 CNVs, 205 inversions, and 20, 437 large 
indels. We also identified 49,419 haplotype blocks by phasing heterozygote 
SNPs in long mate-paired reads, which reconcile with 60.19% of HapMap-
phased genotypes from the CHB/JPT population. This study represents the 
first systematic comparison and combination of two different NGS 
platforms for human genome re-sequencing. 
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THE SOCIAL, POLITICAL, AND ECONOMIC IMPACT OF 
PERSONAL GENOMES. 
 
Dan M Bolser, Jong H Bhak  
 
Personal Genomics Institute, Bioinformatics, Seoul, 0, South Korea 
 
Knowledge of the personal human genome promises many opportunities but 
presents many challenges. I intend to discuss the broad social, political, and 
economic impact of this knowledge with illustrations from the literature.  
 
Disease genetics: Predicting an individuals spectrum of disease susceptibility would 
provide significant savings to the health-care system. (Common diseases cost the US 
an estimated 600 billion dollars every year.) However, the implications of such a test 
on private health insurance is unclear. Does knowledge of our genetic individuality, 
therefore, require governmental protection? 
 
Lifestyle genetics: New service-industries based genetic information could 
potentially improve our quality of life. For example, diet advice targeted to our 
particular tastes, allergies, and metabolism could help us stay healthy, exercise 
programs targeted to our likely abilities would be rewarding, and education targeted 
to our likely cognitive profile would be effective. However, the social implications 
of genetic determinants of behavior have yet to be fully comprehended. How can 
society cope with the knowledge that some individuals could be genetically more 
prone to violence, for example? 
 
Given that our alleles have evolved to equilibrium over tens of thousands of years, 
does it become advantageous to seek to shift the balance to match our modern 
lifestyles? For example, alleles underlying problems such as diabetes and obesity 
were once advantageous. In theory, these disease causing alleles could be 
technologically excised from the gene pool. Or is this idea so fundamentally 
abhorrent that it should not even be discussed? Is science simply going too far? 
 
Robustly addressing these challenging questions requires a dialogue with the 
broadest possible participation from all areas society. Throughout history, almost 
every scientific discovery has been misused. I believe that this kind of discussion is 
essential to allow us to collectively and rationally determining the path of the future. 
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RECENT ADVANCES IN SEQUENCE HOMOLOGY ASSESSMENT IN 
THE DIFFERENCE SET SPACE WITH APPLICATION TO THE 
ANALYSIS OF HUMAN GENOMES 
 
Andrzej K Brodzik  
 
MITRE, Emerging Technologies, Bedford, MA, 01730 
 
With the advent of personal genomics and the rapidly approaching 
availability of thousands of human genomes, the capability to compare 
multiple very long DNA sequences at high resolution and at low 
computational cost is becoming increasingly important. Yet, it is apparent 
that, in general, the progress in computing technology has not kept in step 
with the advances in DNA sequencing. To address this incongruence, new 
ways of approaching the DNA sequence comparison problem need to be 
invented. While undertaking such an attempt, it is reasonable to postulate 
some sort of divide-and-conquer approach. This can be realized, for 
example, by taking advantage of the high degree of homology of the DNA 
sequences under consideration. In such an approach, sequence comparison 
can be performed in two stages. First, sequence similarity is assessed at 
rough granularity by identification of major sequence variants such as the 
occurrence of large indels. Subsequently these large sequence variations are 
removed and the modified sequences are compared for the occurrence of 
fine grain genomic variations such as SNPs, short VNTRs and short indels.  
This describes the approach we propose in this work. The unique technical 
aspect of our method is the use of novel genomic markers called cyclic 
difference sets. Cyclic difference sets are abstract algebraic constructs that, 
while previously not used in genomics, bring many advantages to molecular 
sequence analysis. These advantages include abundance and uniform 
distribution of difference sets in genomes, multi-scale analysis capability, 
robustness to sequencing errors, and the availability of high-speed 
computational procedures, such as the fast Fourier transform, for 
implementation of the analysis. The latter property in particular permits the 
construction of sub-sampled representations of genomes in the first stage of 
the analysis and obtaining an alignment of these reduced representations in 
a small fraction of the time required by standard techniques.  
In this contribution we elaborate on technical details of the cyclic difference 
set based sequence homology procedure, apply the approach to human 
DNA data, assess the abundance and distribution of the new markers, and 
detect SNPs.  
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DIFFERENTIAL EFFECT OF THE RS4149056 VARIANT IN SLCO1B1 
ON MYOPATHY ASSOCIATED WITH SIMVASTATIN AND 
ATORVASTATIN 
 
Liam R Brunham1, Peter Lansberg2, Colin J Ross1, John J Kastelein3, 
Michael R Hayden1  
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Amsterdam, 1100 DD, Netherlands 
 
Statins reduce cardiovascular morbidity and mortality in appropriately 
selected patients. However, statin-associated myopathy is a significant risk 
associated with these agents. Recently, variation in the SLCO1B1 gene was 
reported to predict simvastatin-associated myopathy. The aim of this study 
was to replicate association of the rs4149056 variant in SLCO1B1 with 
severe statin-associated myopathy in a cohort of patients using a variety of 
statin medications and to investigate the association with specific statin 
types. We identified 25 cases of severe statin-associated myopathy and 84 
controls matched for age, gender, statin type and dose. The rs4149056 
variant in SLCO1B1 was not significantly associated with myopathy in this 
group as a whole. However, when subjects were stratified by statin type, the 
SLCO1B1 rs4149056 genotype was significantly associated with myopathy 
in patients who received simvastatin, but not in patients who received 
atorvastatin. Our findings provide further support for a role for SLCO1B1 
genotype in simvastatin-associated myopathy, and suggest that this 
association may be stronger for simvastatin compared to atorvastatin. 
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Melbourne, VIC, Australia 
 
Can high throughput sequencing identify causal genes underlying isolated 
cases of rare disease? Several studies to date have successfully identified 
causal Mendelian variants by using multiple affected individuals from the 
same family, or unrelated individuals with exquisitely similar phenotypes. 
Here we present an alternate strategy applicable to even individual, sporadic 
cases of a disease. 
 
We applied medical sequencing to elucidate the molecular basis of rare 
mitochondrial diseases. These disorders collectively represent the most 
common inborn error in metabolism. They are clinically heterogeneous, 
with severity ranging from neonatal fatality to adult-onset 
neurodegeneration, and can show variable involvement of many different 
organ systems. Mutations in the mitochondrial genome account for only 15-
20% of cases, so the vast majority are nuclear in origin. Although nearly 
100 causal genes have already been identified, cohort studies suggest that 
many more await elucidation. 
 
To systematically identify the molecular basis of mitochondrial diseases, we 
performed targeted sequencing of candidate genes in a cohort of well-
phenotyped patients. First, we prioritized genes related to mitochondrial 
function based on clues from integrative genomics. Next, we identified 
sequence variants predicted to impact protein function. We focused 
specifically on ‘recessive-type’ variants (homozygous or two heterozygous 
variants in the same gene), as these showed a twofold enrichment compared 
to controls. Most importantly, we established pathogenicity via cDNA 
complementation in patient-derived fibroblasts that exhibit biochemical 
defects.  
 
Using this approach, we have identified two novel genes underlying 
sporadic cases of mitochondrial disease. In principle, our approach is in 
principle applicable to any disease for which a cellular model exists.  
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IMPROVED METHODS FOR RRNA REMOVAL AND MRNA-SEQ 
LIBRARY PREPARATION. 
 
Roy Sooknanan1,2, John Hitchen2, Anupama Khanna1, Agnes Radek1, 
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H4R2E9, Canada, 3EPICENTRE Biotechnologies, Market Development, 
Madison, WI, 53713 
 
Deep sequencing of mRNA (mRNA-Seq) is rapidly replacing microarrays 
and other analytical methods for transcript profiling, discovery of novel 
transcripts, and identification of alternative splicing events. 
 
Existing library preparation methods are time-consuming, multi-step 
processes that are dependent on intact (nondegraded) total RNA samples, 
the efficient removal of ribosomal RNA (rRNA), the ligation of platform-
specific adaptors, and require multiple clean-up steps to generate di-tagged 
cDNA. We describe simplified protocols for preparing directional RNA-Seq 
libraries from either intact or fragmented RNA samples.  
 
To remove rRNA from either intact, archived (e.g. FFPE), or otherwise 
compromised RNA samples, we have developed a novel procedure 
(RiboZero™ technology) that removes >98% of intact or fragmented rRNA 
from 100 ng to 5 µg of total RNA in less than 90 minutes. 
 
We have also developed a streamlined method to prepare directional RNA-
Seq libraries from rRNA-depleted mRNA samples, in less than 4 hours, 
without the need for cDNA fragmentation, adaptor ligation or gel 
purification. The ScriptSEQ™ procedure uses random primers for first-
strand cDNA synthesis and a single-tube method to generate strand-
specific, di-tagged cDNA fragments compatible with the Roche 454 or 
Illumina GAII platforms. The resulting RNA-Seq library exhibits nearly 
equal representation of the 5’ and 3’ regions of mRNA sequences, as well 
as a high correlation to the original RNA content for both intact and 
fragmented RNA samples. 
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MEDICAL GENOMICS OF PRIMARY IMMUNODEFICIENCIES 
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The genetic basis of many primary immunodeficiencies is still unknown. 
Here we integrate full exome sequencing, transcriptome profiling and 
clinical data with the objective of understanding the molecular mechanisms 
underlying these immunodeficiencies. We have analysed eight cases 
diagnosed with uncharacterized immunodeficiencies, including sporadic as 
well as cases with family history. We present an approach integrating full 
exome and RNA sequencing of the leukocytes from both patients and 
relatives. Classification of validated coding variants (nonsynonymous, 
nonsense, frameshift), and filtering for common and previously described 
variants and the predicted functional effect generated a list of candidate 
genes. Complementing this information with the patterns of inheritance in 
each family and gene expression data restricted the list to a few candidate 
genes. Integrating network analyses and endophenotypic information 
further shed light on the genes likely involved in the etiology of the disease. 
Functional validation of candidate mutations will be carried out.  
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IDENTIFICATION OF INDIVIDUALS WITHIN STUDY COHORTS 
WITH UNUSUAL INTERMEDIATE PHENOTYPES 
 
Vicky E Cho, Rohan B Williams  
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Whole-genome sequencing on individuals is offering a powerful new 
approach to dissecting genotype-phenotype architecture in human health 
and disease. Recent studies have highlighted the difficulties in identifying 
genomic (or epigenomic) correlates of physiological- or behavioural-level 
phenotypes, suggesting that more detailed phenotypic characterisation of 
individuals may improve the utilisation of re-sequencing technologies. 
Intermediate phenotypes, namely mRNA, protein or metabolite levels, offer 
an ideal phenomenological level for more targeted phenotyping. Here, we 
address this issue by developing methodology for identifying individuals 
that demonstrate unusual characteristics in global mRNA levels, and 
illustrate this approach using expression microarray data from CNS-tissue 
in 135 normal human subjects (Myers et al, 2007). To characterise inter-
individual differences in gene expression, we measure inter-individual co-
variance using a robust version of the Mahalanobis distance statistic. Rather 
than attempt to analyse global expression differences between individuals, 
we focus on analysing inter-individual differences that are present in gene-
sets, (i.e. a set of genes that share some common properties, e.g. co-
regulation, membership of a known signaling pathway, etc). We then adapt 
multivariate outlier methods to identify individuals that demonstrate 
unusual patterns of expression in a given gene set with respect to the rest of 
the cohort. Due to the complex co-variance structure of microarray data, we 
have developed procedures to distinguish whether an individual’s status as 
an “outlier” is not simply related to unusual distributional properties of the 
underlying microarray data. Our approach could be used to target 
individuals in large study cohorts, in which molecular phenotypic data have 
been assayed, for aberrant expression of either known or putative pathways 
or functional gene sets. The ability to identify such individuals could be 
critical in pinpointing subjects for further, more targeted assessment: for 
example, more extensive genotyping or resequencing, assessment of 
subject-specific environmental influences or more intensive clinical 
phenotyping. 
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A COMPILATION OF RARE FUNCTIONAL VARIATIONS FROM 
HUMAN EXOMES 
 
Murim Choi, Weizhen Ji, Mathieu Lemaire, Clara Men, Richard P Lifton  
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The common variations in the human genome have been successfully 
captured by the Hapmap project. However, publicly available personal 
genomes and the 1000 Genomes Project have not yet met the demands of 
completely covering rare variations. Whole exome sequencing has been 
proven as an efficient way of discovering disease-causing variations in the 
functional elements of human genome. Here we report a compilation of 
very low frequency variations (down to 0.002) that are novel to the public 
databases. From 250 exomes, we detected 52,120 novel single nucleotide 
variations unique to the three public databases (dbSNP, personal genomes 
and 1000 Genomes). In comparison, 9 personal genomes added 2,211 
exomic SNPs and 1000 genomes added 29,363 exomic SNPs unique to 
dbSNP. Among our novel SNPs, 40,242 have an allele frequency of 0.2% 
and 32,446 are expected to alter amino acid sequences. Specificity of the 
SNPs is >99% based on the empirical verification of the variations. This set 
of SNPs will enable better understanding of the functional rare variations 
and more efficient identification of damaging variations. In addition, with 
data from whole exome sequencing being accumulated at the increasing 
rate, it will be feasible to complete the map of functional variations in the 
near future. 
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AUTISM 
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Medical resequencing of autosomal recessive genetic disorders will likely 
be one of the first areas impacted by low-cost whole-genome resequencing 
using next-generation technologies. To gain a first glimpse into the utility 
and challenges of whole-genome-sequencing in autosomal recessive 
disorders, we report genomes of 8 individuals across a total of 5 families 
exhibiting an autosomal recessive form of inherited autism. Each family 
was independent, contained 5 to 6 children above age 4, and had 2 children 
classified as affected where the underlying causative genetic variant was 
unknown. Sequencing was to a depth of 15-20x on the SOLiD platform 
with 50bp mate-paired reads. Only 1 to 2 individuals were sequenced per 
family, though all accessible individuals within the nuclear family were 
whole-genome genotyped. To aid in identifying the causal genetic variant, 
we describe and characterize an analysis and annotation pipeline for 
identifying SNPs, small and large indels, copy number variants, inversions, 
and translocations. Four approaches for assessing the pathogenicity of a 
genetic variant are investigated. First, we evaluate screening of existing 
SNPs/indels using dbSNP and OMIM. Second, we utilize high-coverage 
exome- and whole-genome individuals sequenced as a resource for 
identifying non-pathogenic genetic variants. Third, we assess feasibility of 
low-coverage 1,000 Genome sequence data as a prior, only investigating 
reads aligning to the variant for a limited number of positions. Finally, we 
examine existing bioinformatic prediction algorithms, such as SIFT and 
Polyphen, for classifying variants unique to our affected individuals and 
polymorphic within the ‘healthy’ individuals. 
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At the Medical College of Wisconsin and the Children’s Hospital of 
Wisconsin, we are using whole genome sequencing to identify disease 
associated variants in patients. Comparison of the patient genome sequence 
against a human reference genome can be expected to identify in the order 
of half a million novel variants and approximately 3.5 million variants total. 
Significant effort is therefore required to analyse this data in order to 
identify the subset of variants with probable disease associations. In order to 
support the team members tasked with identifying the variant(s) likely to be 
responsible for a particular disease, we have developed Carpe Novo, a 
system for storing, managing, and annotating variants identified by whole 
genome or exome sequencing. This system supports geneticist based 
identification of mutations associated with diverse diseases.  
A wealth of data, including conservation scores, genic/genomic location 
(inclusive of alternate transcripts), Polyphen and SIFT predictions, splice 
site predictions, amino acid properties, disease associations, novelty, allele 
frequency, and gene annotation, is generated or extracted for each variant.  
Queries can be run to identify variants meeting certain criteria, for instance 
based on knowledge of the mode of inheritance or likely population 
frequency. Alternatively, variant report pages can be browsed by 
chromosomal position or by gene list; the latter allowing researchers to 
focus on only those variations that exist in a particular set of genes of 
interest. Analysts tasked with identifying likely sequencing or mapping 
errors can also tag variants in the tool; these tags can be incorporated into 
the queries to exclude misleading variants from geneticist review. Variants 
can also be tagged as being benign, pathogenic, or of unknown significance, 
allowing the geneticist to compile a list of candidate mutations for 
subsequent review.  
Following interpretation of the data in light of the patient’s clinical 
presentation and family history, the tool can be used to generate a report of 
the results of the clinical sequencing. This can be modified as the geneticist 
sees fit before printing and approval.  
Use of this tool has proved to be both cost effective and time saving, and 
one that we have been able to implement in-house with relative ease.  
 21 
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1Washington University School of Medicine, The Genome Center, St. 
Louis, MO, 63108, 2UNC School of Medicine, Department of Genetics, 
Chapel Hill, NC, 27599 
 
Thorough analysis of the progression of cancer in specific patients can offer 
great insight into the genetic and molecular markers of the disease, as well 
as the possible environmental influences affecting the ability of healthy 
tissue to regulate and restrain the development of tumor and metastasis 
tissues. In this study of a single patient, we have sequenced samples of their 
primary tumor, liver metastasis, lung metastasis, and some normal tissue, 
achieving average coverage levels of 28.7X, 33.2X, 35.4X, and 32.6X, 
respectively, using a whole-genome sequencing approach. We have further 
validated over 100 somatic SNVs in these 4 samples using deep-readcount 
sequencing technology. Although many of the SNVs found in the tumor 
sample are also found in the metastasis samples, there are many SNVs 
wholly unique to the metastasis samples. Moreover, this metastasis-unique 
set includes some SNVs found only in the liver metastasis and not in the 
lung metastasis, and vice-versa. We conclude that the differential mutation 
frequencies between primary and metastatic breast tumors suggest that the 
primary breast tumor is heterogenous, and that the metastatic tumors may 
arise from a subpopulation of cells within the primary tumor. The unique 
mutations identified in the different metastatic sites suggest that “new” 
mutations develop under distinct environmental influence and selection in 
those sites. 
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During tumor progression, culprit genes and variants confer selective 
advantage to progenitor cancer cells via allowing them to bypass normal 
growth control mechanisms. Both regions of somatic amplification as well 
as germline DNA sequence represent variants that are selected for along the 
tumor genome. High throughput sequencing of tumor and normal tissues 
identifies such somatically amplified regions and holds the potential to 
reveal the specific gene variants being amplified. We propose a novel 
Hidden Markov Model-based method -- Haplotype Amplification in Tumor 
Sequences (HATS) -- that analyzes tumor and normal sequence data to infer 
amplified alleles and haplotypes in regions of copy number gain. HATS 
also utilizes existing information from public repositories (e.g. 1000 
Genomes Project) in order to infer haplotypes. Our method is designed to 
handle biases in read data as well as accomodate rare variants. We assess 
the performance of HATS using simulated amplified regions generated 
from varying copy number and coverage levels. We demonstrate that HATS 
infers amplified haplotypes more accurately than naive haplotype 
construction that is based on allelic read counts alone, especially at lower 
coverage levels. We thus believe our method will help further the 
integration of variant types in sequence data and aid the cancer community 
in identifying causal variants. 
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Next generation sequencing has given rise to several new research 
challenges such as standard format for representation of normal/ variation 
data, efficient storage/ retrieval of thoroughly annotated genomic regions, 
its integration and comparison with clinical information and intuitive 
visualization. We evaluated several existing algorithms in terms of 
specificity, interoperability, data handling capacity and interactive 
environment. Based on this analysis we designed MutML, an XML based 
format that stores sequence, its variants (SNP, indels) and associated 
information (position, functional implications, frequency, etc.) in an 
unambiguous manner and is interoperable in a multi modal environment. 
Information was then linked to the various annotation tables (converted into 
a singular format) from various public repositories (NCBI, UCSC, Ensembl, 
etc). These were further subdivided into multiple classes such as structural/ 
functional, normal/ disease causing variations, etc. Several pattern 
recognition approaches (template matching and k-Nearest Neighbour) are 
applied to determine the patterns in a disease specific module where clinical 
information is also being integrated. 
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Orphan Mendelian recessive diseases are individually rare, but collectively 
constitute a major healthcare burden, causing significant childhood 
morbidity and mortality. Indeed, 20-30% of all infant deaths and 11% of 
pediatric hospital admissions are related to genetic disorders. In 
collaboration with the Beyond Batten Disease Foundation, the National 
Center for Genome Resources is developing a carrier screening test for a 
panel of more than 400 recessive genetic conditions that cause death or 
catastrophic illness in childhood. The test uses enrichment of the exons, 
splice junctions and selected intronic segments of the genes, followed by 
multiplexed next-generation sequencing. Automated bioinformatic analysis 
is used to identify carrier status and zygosity for known and novel 
mutations. 24 previously identified carriers of 17 different autosomal 
recessive diseases and 1 X-linked recessive disease were obtained from 
Coriell Cell Repositories and enriched for 437 genes (approx. 2 megabases) 
using both Agilent SureSelect and RainDance and subjected to multiplexed 
deep sequencing using the Illumina GA IIx. To further assess sensitivity 
and specificity of mutation detection, 26 well-characterized HapMap 
samples, 2 previously sequenced twins, and an additional 52 carriers of 
recessive or X-linked recessive diseases were enriched using an optimized 
Agilent SureSelect bait library and sequenced on an Illumina HiSeq 2000. 
Initial estimates indicate that members of the sample population on average 
carry potential disease causing SNPs in 4-5 of the 437 genes screened. 
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Patients’ personal genome sequences will become available to clinicians 
within the next few years. The availability of such information will raise 
major challenges in areas such as its interpretation and application to 
medical practice. Existing medical school curricula in genetics may not 
prepare students well to work with such data. 
 
What will tomorrow’s doctors need to know to help them apply personal 
genome information in the clinic? We have used the Delphi technique to 
survey the views of (i) experts in genomics, clinical genetics and genetic 
pathology and (ii) current students on the graduate entry medical course at 
Oxford University.  
 
Medical curricula are already very full. If the time in medical training 
allocated to genetics does not change, some currently taught material will 
have to be discarded. An associated challenge will be the integration of 
genomics education into teaching in mainstream medical and surgical 
disciplines. 
 
The results of this study provide an assessment of the educational needs in 
genetics of the next generation of medical graduates. 
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In recent years our understanding of human genetic variation has been 
expanded to include structural variation, which comprises large genomic 
copy-number variants and inversions. Copy-number variants (CNVs) 
account for a more variable number of base pairs between individuals than 
single nucleotide variants (SNVs), contributing to the phenotypic variability 
between individuals. The advent of personal genome sequencing enables us 
to explore the landscape of structural variation in given individuals; 
facilitating the study of the dynamics of this type of variation, the 
mechanisms that generate it and the genomic context. 
 
We attempt to provide a comprehensive view of CNVs in a family of four, 
including both parents and two siblings. We have performed array 
comparative genomic hybridization (aCGH) in all the members of this 
family, as well as whole genome sequencing (WGS) in the two siblings in 
order to survey the number and location of CNVs throughout their 
genomes. Most of the variants have already been identified in other studies 
and can be found in the structural variation databases; however, we also 
identified a few not previously reported CNVs. We assessed the 
transmission states and de novo rates of these CNVs by comparing the 
CNVs in the offspring versus those in the parents. We identified 
approximately 2% of the variants in the offspring to be potential de novo 
events not found in either of the parents. In addition we have refined the 
breakpoints of some of these CNVs in order to elucidate the possible 
mechanisms that have given rise to these CNVs and that generate de novo 
CNVs from generation to generation. From these, we can recognize that 
CNVs account for a greater number of variable base pairs changes from 
generation to generation in contrast to the estimated 10-8 locus specific rate 
for SNVs and recently reported 28 (10-9) genomewide de novo SNV 
changes observed by personal genome sequencing. These observations 
further highlight the importance of CNVs as drivers of evolution and inter-
individual variability. 
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High throughput sequencing opens a window to detect new, rare variants 
affecting complex traits. However, genomewide sequencing is typically 
resource constrained to scales below the thousands of individuals needed to 
for sampling a rare variant in sufficiently many copies for powered 
association testing. We reason that in a bottleneck population, sequencing a 
few individuals directly ascertains variants from the population bottleneck 
that may be rare elsewhere, and can be imputed to a larger sample relying 
on shared haplotypes detected in SNP array data. 
 
We present data and analysis on seven sequenced individuals from the 
bottleneck population of Pacific island of Kosrae, Federated States of 
Micronesia, where multi-trait GWAS had been conducted. We report 
identification of long regions with haplotypes co-inherited between pairs of 
individuals and methodology to leverage such shared genetic content for 
imputation. Our estimates show that sequencing as few as 40 personal 
genomes allows for imputation in up to 60% of the 3,000-person cohort at 
the average locus. We ascertained a pilot data-set of whole-genome 
sequences from four Kosraean individuals, with average 4X coverage. This 
dataset identified 4,567,947 unique single nucleotide variants in total, with 
1,075,708 previously un-annotated. These Kosraen variants are unusually 
enriched for alleles that are rare in other populations. We specifically 
interrogated two regions implicated in Kosraens by haplotype-based 
association with Hemoglobin A1c (P=1.66E-23, 10.1% frequency) and 
Total Cholesterol (P=2.94E-10, 4.4%). Variants in these regions were 
validated in three additional low-pass Kosraen personal genomes, for a total 
of three HBA1c carriers and four TC carriers. In both regions, we report 
novel, functional variants present exclusively in the carriers, including a 
large deletion associated with HBA1C. This effort presents a first study of 
association using whole genome sequencing. 
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Exome sequencing has emerged as a powerful and cost-effective method for 
mapping functional genetic variation. These rapidly accumulating data also 
serve as a model for future large-scale comparison of personal genomes. 
The typical approach to variation discovery relies upon mapping short reads 
to the reference genome, however due to the limitations of short read 
alignment these analyses are inevitably biased against larger (e.g., >20bp) 
INDELs and structural variants (SVs). To overcome this limitation we have 
developed an exome analysis pipeline based upon local de novo assembly. 
Here we describe the key features of this pipeline, including technical 
modifications that increase sensitivity, accuracy and speed. We present 
initial results from an analysis of ~20 human exomes. We find that, 
compared to standard alignment-based methods, exon assembly identifies 
similar numbers of SNPs and small INDELs yet also reveals additional 
classes of genetic variation including large INDELs, local rearrangements, 
transposon insertions and retroposed genes. While “large” exonic variants 
are far less abundant than SNPs and small INDELs, they comprise a 
nontrivial and functionally potent fraction of coding variation. Finally, a 
key strength of exon assembly is the ability to directly resolve haplotypes. 
We identified numerous exons with 2 or more linked variants but also find 
that extant short-read assembly algorithms are poorly suited for resolving 
complex patterns of allelic variation. We discuss our ongoing efforts to tune 
short-read assemblers for this purpose. 
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The advent of routine human whole genome sequencing creates an 
opportunity to provide an accurate, comprehensive and cost-effective 
catalogue of germline variation for an individual. The process of sequencing 
and delivering genomes for individual use must be driven by clinical and 
educational opportunities balanced by addressing ethical concerns and 
regulatory requirements. Using guidelines issued from professional and 
accrediting agencies as well as an independent ethics board, we developed 
and launched individual genome sequencing (IGS) as a physician-led 
service. A physician orders the sequence and obtains informed consent from 
the individual; the sample is sequenced within a CLIA licensed laboratory 
and after a series of quality checks the sequence is returned to the physician 
for communication back to the individual. The sequencing platform and 
process were validated for accuracy and precision, and accredited following 
review by a College of American Pathologist (CAP) inspection team. Each 
individual genome is sequenced at >30 fold coverage using paired 100-base 
reads. Resulting sequence information is provided for approximately 95% 
of the human reference genome, the remainder being mostly recently 
duplicated repeats where ambiguous read alignment is not permitted in our 
ELAND analysis. On average, we detect over 3 million SNPs most of 
which are previously documented in dbSNP. The overall accuracy of our 
base calling is measured as >99.99% and the accuracy for SNP calling is 
>99.7% based on assessments using multiple methodologies. The aim of the 
Illumina Clinical Services Laboratory is to make Individual Genome 
Sequencing accurate, accessible and clinically relevant for physicians and 
patients through a fully accredited process. Here we have established 
baseline processes, tools, and policies to maximize the benefit to patients 
and minimize potential misuse. Additionally, our ongoing efforts to develop 
clinically relevant interpretation tools for physicians are described in a 
separate abstract (see M. Ross). Individual Genome Sequencing has the 
capacity to replace current genetic testing with a near-complete description 
of the genetic make-up of an individual. Considering this potential, it is 
essential that appropriate policies are developed in consultation with legal, 
regulatory and ethics experts to address information access and use of 
whole genome information. 
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Nearly 20% of people in developed countries work during night-shift, 
commonly referred to as “graveyard shifts.” More than 22 million Americans 
are shift workers (e.g., night-shift, swing-shift, evening-shift); on average, 
Americans are sleep deprived. Disturbances to body’s natural circadian rhythms 
have been suggested to increase risks for variety of diseases, such as insulin 
resistance, coronary heart disease, just to name a couple.  
 
Shifting day-and-night requires humans to alter their bodily circadian rhythms 
which control timing of many physiological processes. Time and light-dark 
cycles are important factors contributing to the entrainment of human 
behavioral activities, such as sleep. Sleep is an indispensable contributor to 
human health; it is required for physical, emotional, and psychological well-
being. Thus, studies probing the underlying mechanisms of human circadian 
regulation will contribute to our understanding of various diseases. 
 
Human circadian rhythm sleep variants were not known to be genetically 
heritable until the discovery and characterization of Familial Advanced Sleep 
Phase Syndrome (FASPS) by Ptacek and colleagues in 1999. FASPS subjects 
showed life-long 4-hour phase shift of their sleep. Individuals who inherited 
specific alleles from parental generations showed highly penetrant autosomal 
dominant behavioral phenotype: early sleep times and early morning awakening 
with good quality sleep. Characterization of the human behavioral phenotype 
for FASPS led to the discovery of its emerging underlying genetic components: 
1) In one FASPS kindred, a mutation in human Period 2 (hPER2) caused 
FASPS ; 2) In another family, FASPS was caused by a missense mutation in 
human Casein Kinase I delta (hCKIδ). These were the first cases where genetic 
mutations were shown to cause FASPS, but these mutations only accounted for 
a small percentage of FASPS kindreds. Thus, future studies will uncover more 
human genes important for circadian regulation of human sleep.  
 
For the project described here, we screened 68 FASPS patients for novel 
variants in human circadian rhythm candidate genes, and subsequently, 
characterized potential effects of specific variants on cellular circadian 
periodicity and regulation. SNP variants in coding and noncoding regions for 
each gene were identified, and novel variants were found, when compared to 
control patient samples and to known databases. To further validate whether 
specific novel SNP variants in two human genes were causative for the FASPS 
phenotype, in vitro cellular assays performed measurements of circadian 
periodicities and in vivo models are currently being engineered using human 
BAC transgenic technologies.  
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Since 2004, CNVs have been discovered to determine what segments of 
human genome are frequently affected by deletion or amplification. 
However, its single-nucleotide level structure and the influence on gene 
expression are still under-ascertained. To characterize the structural and 
functional nature of human CNVs as a whole, we analyzed whole genome 
and transcriptome of 10 Asian individuals using massively parallel DNA 
and RNA sequencing (Illumina genome analyzer) as well as ultra-high 
resolution whole-genome tiling CGH arrays (Custom-designed Agilent 
platform), comprising 24 million probes. We identified ~ 700 accurate 
personal by combining read-depth data of sequencing coverage (average 
read-depth is 25x each individual) and the array CGH data. We 
characterized the precise breakpoint sequences of ~ 60% of the CNVs by 
analyzing the short-reads aligned on near the CNV breakpoint locations 
expected from the CGH microarrays. In addition we attempted to identify 
the location of copy number gain segments using short-read data. From the 
characteristics of breakpoint sequences, the mechanisms for CNV genesis 
are suggested. Then we figured out the influence of CNV on gene 
expression. Generally, CNV affected genes showed weak but positive 
relationship between copy number and expression level. However, 
expression of several specific genes was strongly controlled by CNVs, 
which suggests the potential influence CNVs on phenotypic variations.  
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Personal genome sequencing for cancer patients has the potential to 
dramatically improve our understanding and treatment of this deadly 
disease. Indeed, the complete genome sequences of several human cancers 
have revealed thousands of somatic mutations, a number of which may 
contribute to tumor development and growth. Recently developed hybrid 
selection (capture) technologies, when paired with massively parallel 
sequencing, make it possible to sequence human exomes to high coverage 
in a single instrument run. The abilities of exome and whole-genome 
sequencing approaches to identify somatic mutations in cancer have not 
been systematically compared. 
 
To address this, we applied both whole genome (>30x) and exome capture 
(48 Mbp) sequencing strategies to five ovarian cancer tumors and matched 
(normal) DNA controls using the Illumina GAIIx platform. For exome 
datasets, we assessed target enrichment (specificity) and coverage 
uniformity across 48 megabases of target sequence. We developed novel 
algorithms and filters for mutation detection in regions of variable deep 
coverage. Finally, we validated more than 250 somatic mutations across the 
five genomes, and evaluated the sensitivity and specificity of variant 
detection in both whole genome and exome datasets.  
 
Our results suggest that exome sequencing captures the vast majority of 
somatic mutations in coding regions. Whole genome sequencing, however, 
remains the most unbiased approach to identify somatic events – including 
mutations, copy number changes, and structural variation – in cancer 
genomes. A strategy that employs both exome and whole genome 
sequencing approaches may ultimately yield the comprehensive catalogue 
of somatic mutations in human cancers. 
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The small RNA (<50 nt) transcriptome contains a diverse array of RNA sub-
types ranging from the more well-known miRNAs, piRNAs & siRNAs to more 
recently discovered classes of non-coding RNAs associated with promoter and 
enhancer functions1,2. Furthermore, the biogenesis of these classes of small 
RNAs varies and can result in RNA modifications that hinder the ability to 
capture and identify them from complex RNA samples. We have adapted a 
sequential adaptor ligation technique with the purpose of improving the 
performance and sensitivity of the procedure. That effort is represented by the 
ScriptMinerTM small RNA-seq library prep kit: both for Illumina singleplex and 
multiplex formats. There are several novel improvements for capturing and 
representing small RNAs. First, we have optimized a strategy to degrade excess 
unused 3’ preadenylated adaptor molecules following ligation. The end result is 
to suppress formation of adaptor-only product and improves the overall 
performance of the method. An added benefit to this background reduction 
technique is that RNAs in the sample that contain a cap or 5’ triphosphate are 
converted into ligate-able 5’ monphosphates. This permits the user to capture 
and identify capped or 5’ triphosphorylated RNAs in the sample that otherwise 
would be excluded from the library prep. The result is a more sensitive and 
comprehensive representation of the small RNA repertoire in a sample.  
 
Recent published results strongly suggest that small RNA library methods are 
very reproducible, yet inherently biased in their relative ability to capture and 
identify RNAs in a sample3. One obvious source of this bias is the type of ligase 
used in the sequential attachment of adaptors to the 5’ and 3’ ends of the 
transcripts. To help resolve this issue, we devised a set of samples to investigate 
ligation and representation bias in ScriptMiner library preps. We used a 
combination of both natural samples and synthetic pools of known miRNA 
oligo’s to construct libraries using different ligases or ligase blends. 
Furthermore, a novel RNA control oligo containing degenerate bases was 
spiked into specific samples to ultimately aid in the determination of ligation-
bias due to sequence preference of the enzymes. These samples were all 
sequenced using an Illumina GAIIx platform and the results of this study will be 
presented.  
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New sequencing technologies promise to change the way genomic 
resequencing is conducted in the clinical setting. However, the routine use 
of this technology for diagnostic testing will require genomic selection 
methods that meet rigorous quality standards.  
 
Four genomic selection methods including PCR, Molecular-Inversion 
Probes (MIP), Capture-arrays (Agilent) and In-Solution hybridization 
(Sureselect), were evaluated and compared to an array-based resequencing 
platform, currently offered by the LMM for diagnostic testing. Sequencing 
was carried out on a Genome Analyzer II (GAII) and performance 
characteristics such as sensitivity and specificity, as well as operational 
factors such as cost and turnaround time, were analyzed and compared to 
those of the resequencing-array.  
 
With PCR, five samples enriched for 136 known sequence alterations in 19 
cardiomyopathy genes were analyzed. The sensitivity to detect substitutions 
was comparable to that of the resequencing-array (98%) and GAII 
technology performed better for detecting insertions and deletions (91% vs 
58%). Confirmatory follow up due to false positive calls and low coverage 
was similar to that of the array-based test. However, PCR was expensive 
and did not scale well. 
 
All other selection methods tested proved capable of satisfying criteria such 
as sensitivity for detection of substitutions, with differences in their ability 
to detect ins or dels. However, Capture-arrays, Sureselect and MIPs each 
had limitations in operational factors such as sample batching or pooling, 
ease of development, laboratory staff time, and most importantly: cost.  
 
The suitability of selection method is affected by whether the setting is 
clinical diagnosis or research and this concerns both scientific and practical 
considerations. Successful outcomes are dependent on the purpose of a 
particular application and refinements in genomic selection methods will 
make it possible to translate 2nd generation sequencing into clinical 
practice. 
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NISC Comparative Sequencing Program2  
 
The NIH Undiagnosed Diseases Program began analyzing single families 
with whole exome and whole genome sequencing in October 2009. We 
have completed sequencing 28 whole exomes and 1 whole genome. The 
current plan is to complete 60 exomes and 7 genomes by September 2010. 
There were 8 families chosen with 8 separate disorders: 7 recessive, and 1 
dominant. All families had both parents and at least one affected sibling. 4 
families had skeletal anomalies. 7 had significant neuro-developmental 
phenotypes. Exome capture and sequencing produced an average coverage 
of 78.4% of the UCSC "known genes" sequence. To analyze the sequences, 
high-density SNP array data on these same individuals were used to 
construct linkage regions for recessive, dominant, and conjoint new 
mutations; this excluded up to 80% of the genome for recessive cases with 
two affected children. dbSNP130 data were used as an optional filter. For 
each variation from the reference sequence, every family trio or quartet was 
examined for loci that followed homozygous, compound heterozygous 
recessive, or autosomal dominant (germ line mosaic) new mutation 
inheritance patterns. The final filter used conservation information by the 
CDPred algorithm to prioritize candidate variants by the degree of 
deleteriousness. For the single case of consanguinity, there were 113 
variants consistent with Mendelian regional linkage; 27 were not in 
dbSNP130. Only 2 had significant CDPred scores. One variation was 
identified and verified to be a homozygous mutation in AFG3L2, the first 
recessive diagnosis involving this gene. For the other families, we have 
between 68 and 201 viable candidates that pass all exclusion constraints. 
These candidates are being evaluated using additional bioinformatics and 
laboratory assays; further data analysis of the remaining exome and genome 
sequencing are ongoing. 
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Ketosis-prone diabetes (KPD) is a widespread, emerging, heterogeneous 
syndrome, characterized by patients who present with diabetic ketoacidosis 
or unprovoked ketosis, but do not necessarily have the typical phenotype of 
autoimmune type 1 diabetes. Mulitple, severe forms of β-cell dysfunction 
appear to underpin the pathophysiology of KPD syndromes. Until recently, 
the syndrome has lacked an accurate, clinically relevant, and etiologically 
useful classification scheme. We have utilized a large, longitudinally 
followed, heterogeneous, multiethnic cohort of KPD patients to identify 
four clinically and pathophysiologically distinct subgroups that are 
separable by the presence or absence of β-cell autoimmunity (“A+” or “A-“) 
and the presence or absence of β-cell functional reserve (“β+” or “β-“). The 
resulting “Aβ” classification system of KPD has proven to be highly 
accurate and predictive of such clinically important outcomes as glycemic 
control and insulin dependence, as well as a guide to biochemical and 
molecular investigations into novel causes of β-cell dysfunction. Here, we 
describe our recent findings regarding their pathophysiology using (a) 
immunologic markers that distinguish the two “A+” KPD subgroups from 
each other, (b) genetic variants from several genes including PDX1, 
TCF7L2, ZnT8 (SLC30A8), and GIPR that have been associated with other 
diabetic syndromes, and metabolic assays that distinguish the two “A-” 
KPD subgroups from each other. These data are presented, providing 
insights into novel “intermediate” forms of diabetes, as well as hitherto 
unexplored immune and non-immune mediated mechanisms of β-cell 
dysfunction. 
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Using high-throughput DNA sequencing to study the genetic 
polymorphisms present in an individual’s genome is a powerful discovery 
application that does not require imposing prior expectations on the 
experimental method, which is a limitation of design-based techniques such 
as SNP arrays. With the continued advances in DNA sequencing 
technology, the genomics community has reached a point where studying 
large data sets on the order of gigabases per individual genome is expected 
to be cost effective. During the past year, human exome solution capture 
kits have become commercially available from NimbleGen and Agilent. 
The increased simplicity and throughput capability of these kits have 
resulted in their quick adoption by many scientists as a tool for capturing all 
of the exons in the human genome. To properly evaluate the completeness 
of human exome solution capture kits, we are studying the actual coverage 
of all known human exons provided by our captures and the consistency of 
SNP discovery between replicate captures. To qualify whole exome 
sequencing relative to whole genome sequencing, we are also studying the 
agreement between the SNPs identified from capture data and those 
identified from whole genome sequence data. For our analyses, we have 
chosen the individuals in the European (CEU) and the Yoruban (YRI) trios 
sequenced in Pilot 2 of the 1000 Genomes Project. We are analyzing both 
the SNP calls and the raw sequence data generated by the 1000 Genomes 
Project from the six individuals, and we have completed solution captures 
with DNA from these individuals using the NimbleGen SeqCap EZ Human 
Exome Library SR kit and the Agilent SureSelect Human All Exon kit. To 
produce sequence data from our captures, we allocated one lane of paired-
end 76-cycle Illumina sequencing per individual. We have built a capture 
analysis pipeline for our data, which encapsulates the BWA and SAMtools 
programs written by Heng Li (Broad Institute) with custom scripts, in order 
to define capture efficiency and to identify SNPs. Our analyses will also 
particularly focus on Mendelian variants in genes to illustrate important 
differences between whole exome sequencing and whole genome 
sequencing. 
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NCBI maintains a set of databases that archive, process, display and report 
information related to germline and somatic variants from multiple species. 
These databases, primarily the Database of Single Nucleotide 
Polymorphisms (dbSNP) and the Database of Genomic Structural 
Variations (dbVar), are integrated with many resources at NCBI including 
dbGaP, Gene, GeneTests, OMIM, PubMed, and Nucleotide. Variations 
submitted to either database based either on flanking invariant sequence or 
locations asserted on reference sequences are assigned unique database 
identifier (ss# in dbSNP or nsv#/esv# in dbVar). These submissions are then 
processed to aggregate information from multiple submitters (assign rs# in 
dbSNP) and annotated on each version of a genome, RefSeqGenes (LRG), 
and other RefSeq sequences. Because these stable public accessions are 
citable in publications, they facilitate aggregation of information as diverse 
populations are tested for variation. Researchers and genetic testers are 
encouraged to submit their variation data and to cite their submissions in 
manuscripts and on the web. Once data are accessioned, they are made 
available in diverse ways: Entrez searches, study-specific reports, 
annotation on the genome, human gene-specific displays such as Variation 
Viewer, and ftp transfer. This presentation will highlight recently added 
search and display options and new variation FTP downloads such as for 
the Variant Call Format (VCF) reports and human gene-specific reports. 
dbSNP and dbVar represent millions of human variants from major 
populations and individuals, including variations from Venter, Watson, 
Chinese, and Korean personal genomes. There are more than 7 million 
variants having minor allele frequency > 0.05 in at least one population and 
more than 5 million validated by genotyping. They also contain thousands 
of records with possible ‘clinical significance’. Data are integrated from 
large scale international projects such as the Human Genome Project, 
International HapMap Consortium, DGV/DGVa, 1000 Genomes Project, 
and from highly-curated Locus Specific Databases (LSDBs), OMIM, the 
literature, or other gene-specific resources. Given our ever-increasing need 
for understanding of human variation, maintenance and effective use of 
centralized variation databases is critical.
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Targeted selection and high-throughput sequencing of entire human exomes 
is a powerful technology for unraveling the etiology of monogenic 
disorders. However, extending this approach to identifying the missing 
heritability of complex disorders will be far more complicated. By the end 
of 2010 many thousands of exomes are likely to have been sequenced. 
These and future data will permit an informative assessment of the 
landscape of functional mutations according to, for example: gene ontology, 
disease etiology (e.g., OMIM), conservation, and pathway membership. 
Such comparisons will facilitate future studies investigating complex 
diseases by allowing researchers to “weight” observed mutations in large 
cohorts by the expected scope of mutation in a given gene or molecular 
pathway. Here we present an initial description of this spectrum from 
approximately 20 human exomes and describe a comprehensive pipeline to 
detect all classes (i.e., SNPs, INDELs and SVs) of functional genetic 
variation. 
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The sequencing revolution currently underway has made it extremely easy 
to sequence all of the short RNAs present (the short RNA-ome) in a given 
cell type at a given stage. It has been observed that the short RNA-ome in 
the 20-30bp range is dominated by microRNAs, regulatory RNAs which 
have been implicated in a wide variety of human diseases from 
schizophrenia to cancer and are defined by a characteristic stem-loop 
precursor structure and deep conservation. While there has been some study 
of genomic changes in miRNA precursors and their effects on function, 
very little is known about the interplay between genomic changes in 
precursor sequence and possible downstream effects on miRNA expression 
and function. 
 
In this study we have sequenced 272 brain-implicated miRNA precursors in 
141 control and 141 affected samples finding 103 precursor variants in 73 
of the 272 miRNA genes tested. Computational modeling of the effects of 
these variants on structure show a tendency toward stabilization, though it is 
likely that precursor role (mature miRNA seed region, cleavage site, etc) at 
the variant position is more important than overall structure. To better 
capture the possible functional effects of any genomic variation in miRNA 
precursors we have developed a miRNA variant annotation system based on 
structural effect and precursor role, and attach significance based on 
projected impact of the variant on miRNA processing and activity. 
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The Critical Assessment of Genome Interpretation (CAGI) is a community 
experiment to evaluate computational methods for predicting the 
phenotypic impacts of genomic variation. Participants will be provided 
unpublished genetic variants and will make predictions of resulting 
phenotype. These predictions will be objectively assessed against 
experimental characterizations. The long-term goal for CAGI is to improve 
the accuracy of phenotype and disease predictions of rare variants in clinical 
settings. 
 
CAGI, which is based on the framework of the long-running Critical 
Assessment of Structure Prediction (CASP), will entail four phases: 
 
1. Unpublished associations of genotypes with molecular, cellular, or 
organismal phenotypes will be collected by the organizers from 
experimental and clinical labs 
2. Participants will make computational predictions of phenotypes from 
provided genotypes  
3. Experimental and clinical scientists will assess predictions  
4. A community workshop will be held to disseminate results and 
evaluate our collective ability to make accurate and meaningful predictions. 
 
From this experiment, we expect to understand the diversity of mechanisms 
of genome variation, identify bottlenecks in genome interpretation, inform 
critical areas of future research, and connect researchers from diverse 
disciplines whose expertise is essential to methods for genome 
interpretation. Preliminary data sets we have been offered include 
enzymatic activity of human metabolic enzymes, segregation of rare 
variants identified in from resequencing in cancer cases and controls, 
efficiency of transcription for variants of a checkpoint protein variants, 
pathogenicity of mitochondrial variants, clinical phenotypes associated with 
complete human genomes, and molecular mechanisms underlying GWAS 
disease associations.  For more information, see 
http://genomecommons.org/cagi/. 
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The barriers to accurate human genome re-sequencing have largely been 
surmounted, enabling consideration of routine clinical applications. 
Significant challenges remain, however, for interpretation of whole genome 
data for diagnostic or prognostic purposes. Public data on mendelian 
variants are held in a range of different locus-specific or genomic databases, 
and the largest repository of human diversity data (dbSNP) currently 
contains very limited clinical information. The significance of most novel 
coding variants remains unclear in the absence of other medical 
information. Most importantly, the prediction of phenotype from genotype 
is complicated by variability in penetrance and expressivity, possibly as a 
consequence of other genetic, epigenetic and environmental factors. We 
have established a physician-led clinical service for whole genome 
sequencing (see abstract by T. Hambuch). We explored the feasibility of 
developing a suitable process to identify features of potential clinical 
importance in an individual genome utilizing available public databases, in 
order to provide a report that would assist physicians with genome 
interpretation For our approach, we considered five tiers of variant 
information with varying degrees of immediacy in their clinical impact: (1) 
known monogenic variants with evidence for disease causation, (2) 
pharmacogenetic markers, (3) polymorphisms associated with common, 
complex conditions, (4) novel variants in genes in tier 1, and (5) known 
tissue-type variants. We focused our efforts on Tier 1, where our starting 
point was the Human Gene Mutation Database (HGMD). We observed 16 
homozygous and 48 heterozygous variants considered by HGMD as 
“disease causing” most of which were not compatible with a reportedly 
healthy adult. These variants were manually assessed via literature review, 
locus-specific databases and population frequency information. The 
evaluation resulted in a list of 10 variants with sufficient evidence of 
clinical impact to be considered pathogenic, probably pathogenic or 
possibly pathogenic. Whole genome sequencing holds tremendous potential 
for clinically important information throughout the lifespan. The 
development of interpretation tools is essential to assist the physician in 
understanding and managing the implications of genome information for the 
patient. Ongoing discussions of the ethical, legal and social implications 
around appropriate access and use of this information will guide the further 
development of the interpretation strategy we present here. 
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Autism (MIM209850) and additional autism spectrum disorders (ASDs) are 
pervasive developmental disorders defined by social disability and 
communication impairment as well as repetitive behaviors and/or restricted 
interests. The onset is generally before the age of 3 years, and the disorder 
has a prevalence of 0.6% in the population, affecting ~4 times as many 
more boys as girls. The heritability of autism is estimated at ~90%, making 
it one of the most heritable complex disorders. Linkage and genome-wide 
association studies have not provided substantial insight into the root causes 
of idiopathic autism. Thus we have embarked on an ambitious collaboration 
between experienced large scale sequencing centers at the Baylor College of 
Medicine (BMC) and the Broad Institute (BI) and experienced autism 
genetics research groups to take advantage of dramatic advances in 
sequencing technology to study sequence variation across the entire 
genome. Phase 1 of this study, described here, aims to assess the entire 
spectrum of allelic variation using whole exome sequencing in 1000 cases 
and 1000 matched control samples. Our target parameters for the project are 
a median sample performance with greater than 80% of target bases covered 
at 20x per sample. The whole exome target consists of more than 32 Mb of 
exonic sequence, however, the flanking sequence near each exon also 
receives extensive coverage for analysis. Here, we present the experimental 
and analytic strategy of this study, quality control and detailed coverage 
analysis, as well as initial summaries of the rare and common coding 
variation found in ASDs. The complete dataset will provide a thorough 
assessment of variation found in all genes, allowing for a great range of 
analyses and should, after extension and confirmation of promising results 
in phase 2, yield discovery of genes and pathways currently not implicated 
in ASDs. As such it will provide a significant public resource for autism 
genetics, diagnostics and potential treatment. 
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The University of Tokyo Genome Browser (UTGB) is a web-based genome 
browser for visualizing genome data resources. We are now developing 
UTGB Toolkit for creating internal databases of the UTGB genome 
browsers. With the power of UTGB Toolkit, the users can import various 
types of biological data at ease (e.g., BED, WIG, FASTA, SAM/BAM, 
etc.), and the imported data resources can be used through the web 
servers of the UTGB, which supports both graphical and text/binary 
data outputs. We are currently using UTGB Toolkit as a database server 
for analyzing the relationships between SNPs, methylation, nucleosome 
positioning, gene expressions, etc. 
 
Another feature of our UTGB Toolkit is its portability, enabled by the 
embedded database management system (sqlite-jdbc) and portable web 
server (Tomcat engine). Although setting up a DBMS and web server 
needs significant expertise, UTGB completely does away these 
inconvenience by embedding them into the system. And also, this 
portability makes easier to distribute database servers of UTGB 
Toolkit across several machines. We have observed even a simple 
replication strategy of database servers significantly improves the 
database server performance, which is also useful for quickly browsing 
biological data resources through a genome browser interface. 
 
Our UTGB Toolkit supports interval intersection queries of BED, WIG, 
SAM/BAM format data, etc., and also sub-sequence retrieval queries of 
FASTA files. In addition, UTGB Toolkit uses compressed databases for 
FASTA, WIG files, which needs large volumes of disk storage. Our 
compressed databases efficiently save disk spaces without losing 
database query performance. UTGB Toolkit is an open-source project, and 
its source code is freely available at http://utgenome.org/ 
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The ClinSeq project at NHGRI aims to pilot the use of next-generation 
DNA sequencing technologies in a clinical research setting, with an initial 
focus on cardiovascular disease (CVD). To quantify this phenotype, we 
assess coronary artery calcification levels using computed tomography 
scanning and have formed experimental and control subject groups from the 
two extremes of the calcification score range. Currently, we are piloting the 
Illumina platform to sequence transcriptomes from eight subjects in each 
group, using RNA from whole blood and lymphoblastoid cell lines (LCLs).  
 
Briefly, our experimental approach consists of isolating poly(A) RNA from 
total RNA, followed by fragmentation, conversion to cDNA and sequencing 
on the Illumina GAii platform to generate ~40 million paired-end 51-bp 
reads for each individual. To analyze the data, we have implemented a 
bioinformatics pipeline, which performs quality control checks on each 
transcriptome library, and subsequently analyzes differential gene 
expression levels and alternative splice site usage patterns. Additionally, for 
each subject, this pipeline integrates transcriptome sequence data with 
Illumina whole-exome sequencing data that we have generated to identify 
differences in allelic expression at known heterozygous sites and also to 
screen for potential RNA editing loci.  
 
Initial analysis of differential gene expression in the LCL data shows 97 
genes having changes of twofold or greater between groups, of which 47 
genes were up-regulated in the high-calcification group and 50 genes were 
up-regulated in the low-calcification group. For each of these genes, by 
manually reviewing the count data and inspecting it in the UCSC genome 
browser, we have verified that a high level of within-group variance does 
not cause a false positive call while analyzing differential expression. 
Interestingly, a second set of about a thousand genes shows great between-
individual variability without any between-group consistency. Aside from 
the gene expression aspect, the alternative splicing and allele-specific 
expression components of our pipeline also show evidence of between-
group differences which we are validating and reviewing for clinical 
relevance.  
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An effective strategy for identification of common and rare variants in 
candidate regions in the human genome is critical to understanding the 
etiology of disease susceptibility. Here, we utilize advancements made both 
in massively parallel targeted enrichment and next generation sequencing 
technologies to interrogate genes associated with common cancers using a 
microfluidic PCR-based enrichment method in combination with a next 
generation sequencing platform that is lower in cost and offers more 
flexibility in throughput for routine analysis of various cancer subtypes. We 
present details on targeted enrichment and sequencing of 4000 targeted 
regions include exons, splice junctions, untranslated regions (UTRs), and 
promoters of 142 genes implicated in certain cancers from human DNA 
samples. We demonstrate that this integrated approach provides a highly 
sensitive and specific solution for performing parallel mutation screening 
for tumor samples and cell lines. 
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Our group is developing methods and resources to integrate currently 
unutilized data from Next-gen sequencing datasets into analyses of 
telomeric and subtelomeric DNA. Average telomere length is a highly 
variable, inherited trait as well as a biomarker for biological aging; 
accelerated somatic telomere reduction, loss, and dysfunction are 
characteristic of a wide range of human diseases, including cancer. The 
subtelomere-telomere boundary regions encode TERRA transcripts, non-
coding RNAs essential for telomere integrity and proper assembly of 
telomeric chromatin. These DNA regions are highly variable, and contain 
sequence elements believed to be essential for TERRA transcription, 
regulation of telomere length, and epigenetic regulation of telomeric 
chromatin function.  
 
Telomeric and subtelomeric sequences contain both characteristic simple 
repeats and a set of well-characterized low-copy sequence elements; 
however, because they are both multicopy and variable between genomes 
they are not typically included in analyses of Next-generation datasets 
because these Next-gen reads might not map uniquely to the assembled 
genome using standard methods, or the reads might be derived from 
sequences not included in the standard assembly. We are creating and 
testing a bioinformatic pipeline to selectively capture and analyze in detail 
the subtelomeric fraction of genome-wide next-generation sequence data, 
using our current understanding of telomeric sequence organization. We are 
testing the extent to which full mapping of Next-generation reads to 
subterminal DNA regions can be achieved, and developing novel 
approaches to analyzing telomeric and subtelomeric read data to assess 
telomere length, telomere mutation, sequence features of the telomere-
subtelomere boundary, and mapping of epigenetic marks near telomeres. 
We will present the results of our initial analysis. 
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The rapidly decreasing cost of whole genome sequencing will soon make 
the Personal Genome a reality for large numbers of individuals wanting 
access to and interpretation of their genomic information. Already the 
accessibility of this information is providing an impetus for patient-driven 
research. Though the advent of the truly personal genome, whereby 
everyone has access to their entire genomic data at an affordable price is not 
yet here, a number of options exist for individuals to obtain genotyping data 
from consumer genomic services. As proof of principle of a patient-driven 
clinical trial using personal genomic data in the form of identified SNPs, 
this study utilizes published data from genome-wide association studies 
(GWAS) to link genes and variants to a variety of biomarkers associated 
with human aging.  
 
This study takes into consideration GWAS results for critical aspects of 
aging including the inability to adequately regulate glucose levels, the 
decline of the immune system, ineffective catabolism, shortening of 
telomeres, and defects in lipoprotein metabolism. Genotyping data for a 
group of twenty citizen scientists is reviewed and can be further integrated 
with phenotypic measures of aging (including blood pressure, cholesterol, 
BMI, VO2 max, erythrocyte glycosylation, LDL particle size, telomere 
length, and lymphocyte growth rates), and used as the basis for proposed 
personalized interventions. Citizen-science contributed biobanks and 
databases are examined as a resource for the immediate, cost-effective, and 
large-scale application of research studies.  
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As the cost of sequencing declines, multiple ethical questions arise not only 
from a decision to be sequenced but also from a decision not to be. Our 
family considered the balance between these and decided to proceed. I will 
discuss how we balanced the factors on both sides of this issue. I will also 
discuss lessons learned trying to use family sequencing data and gaps 
between current biology education and skills needed to work with and 
understand genome data. A separate presentation will be made of the 
scientific and medical results. 
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Massively parallel seqeuncing technology is now firmly established in the 
core facilty. With more open access to these technologies researchers are 
beginning to initiate projects within core facilities that bring us closer to 
personalized genomics and, hence, personalized medicine. While 
sequencing of human whole genomes remains outside of the resource limits 
for a majority of researchers studies in targeted resequencing and whole 
transcriptome sequencing for personal genome analysis are quickly 
increasing. The Microarray Core Facility at Baylor College of Medicine 
began offering sequencing services utilizing the Illumina Genome Analyzer 
IIx with paired end capabilities in November 2009. We present our 
experience with targeted resequencing and whole transcriptome sequencing 
for analysis of personal genomes with an eye to the role of a core facility in 
generating data, facilitating analysis, and aiding researchers in experimental 
design. 
 51 
EXPLOITING A HIERARCHICAL CLUSTERING TREE OF GENE-
EXPRESSION TRAITS IN EQTL ANALYSIS 
 
Seyoung Kim, Eric P Xing  
 
Carnegie Mellon University, Machine Learning & Computational Biology, 
Pittsburgh, PA, 15213 
 
Gene-expression traits have been regarded as a highly informative source of 
intermediate phenotypes to study the genetic basis of complex diseases such 
as asthma, diabetes and cancer, because they are more directly influenced 
by the disease-causing genetic variations and reveal the molecular and 
mechanistic basis of clinical phenotypes. However, despite the significant 
differences in dimension, complexity and various statistical properties 
between expression traits and clinical traits, statistical methodologies for an 
expression quantitative trait locus (eQTL) analysis remain largely relying 
on techniques used in classical QTL analysis. For example, although 
subsets of genes can often co-express and their expressions may be 
controlled by a common genetic locus, most of the traditional approaches 
for eQTL mapping relied on analyzing each expression trait separately 
rather than directly combining the association signals across correlated 
genes for a joint inference of eQTLs for all expression traits.  
 
In this work, we develop a new method for eQTL mapping called tree lasso 
that leverages the correlation structure in gene expressions captured by a 
hierarchical clustering tree to jointly analyze all expression traits in a single 
statistical framework for pleiotropic effects. Our approach is based on a 
multivariate regression model with a tree regularization constructed from 
the hierarchical clustering tree, and it provides a natural way of combining 
association signals across correlated genes at multiple levels as specified in 
the hierarchical clustering tree. Our proposed method has the advantage of 
directly making use of the output of the hierarchical agglomerative 
clustering algorithm that has been widely used as a visualization tool of the 
gene co-expression pattern for an exploratory analysis and as a 
preprocessing step for prediction of the disease outcome of individuals 
based on the gene-expression pattern. Using simulated and yeast datasets, 
we demonstrate that our method shows a greater power for detecting causal 
SNPs with fewer false positives than other methods.  
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Since many complex disease and expression phenotypes are the outcome of 
intricate perturbation of molecular networks underlying gene regulation 
resulted from interdependent genome variations, association mapping of 
causal QTLs or eQTLs must consider both additive and epistatic effects of 
multiple candidate genotypes. This problem poses a significant challenge to 
contemporary genome-wide-association  
(GWA) mapping technologies because of its computational complexity and 
a large number of possible SNP-SNP interactions.  
 
We propose a novel regression-based approach for detecting marginal and 
epistatic eQTLs which incorporates genetic interaction networks to model 
epistatic effects while simultaneously considering related traits. First, in 
order to reduce the complexity and increase the statistical power of GWA 
analysis, we select possible interacting SNP pairs using genetic interaction 
networks. Then, we consider these epistatic effects of the pairs of SNPs as 
well as additive effects of SNPs for association analysis. Furthermore, we 
jointly estimate eQTLs and related traits via a structured regularizer which 
induces  
grouping effects among multiple-related traits and between interacting 
SNPs. Our regularized regression model could be efficiently solved using 
coordinate descent method with majorize-minimize algorithm.  
 
We use our method to detect marginal and epistatic eQTLs on simulated 
and real yeast eQTL datasets. In our simulation study, our regression model 
with the structured regularizer significantly outperforms many other 
competitors. Also, in the yeast eQTL datasets we found a large number of 
statistically significant SNP-SNP interactions with false discovery rate at 
0.05 (1,794 SNP-SNP interactions were identified for 5,637 gene traits). We 
will present our results on yeast eQTL datasets including significant 
SNPSNP interactions in yeast genomes and hot spots of epistatic SNPs. 
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Next generation sequencing technologies have dramatically decreased the 
cost of sequencing human genomes. These technologies are enabling the 
1000 Genomes Project - an ambitious undertaking to reconstruct hundreds 
of genotypes and understand the polymorphisms present in the human 
population. Simultaneously, hundreds of individual genomes are sequenced 
via a low-coverage whole-genome  
shotgun approach. However, it is not clear if this low coverage will be 
sufficient to identify a large fraction of the human variation, especially 
structural genomic polymorphisms. Previously, we developed MoDIL 
(Mixture of Distributions Indel Locator), a tool for detecting small indels > 
20bp from high-throughput sequencing matepair dataset. While MoDIL 
demonstrated promising results on high coverage  
dataset, it cannot be applied to 1000 genomes data since most of the 
individuals will be sequenced at a low-coverage. Therefore we need to 
develop methods to identify indels using matepairs sequenced at a low-
coverage from multiple individuals.  
 
We propose a novel approach, MoGUL (Mixtures of Genotypes Variant 
Locator), which can detect common indels in a population using low-
coverage matepair data. Assuming that most polymorphisms are di-allelic, 
we combine matepairs from all the individuals and increase the coverage of 
the matepairs. If indels exist in a particular genomic location, then we 
expect to observe two distributions of mapped distances of  
the matepairs spanning the location; one distribution is from no indel alleles 
and the other is from indel alleles. Now we can enjoy the full distribution of 
mapped distances of matepairs. Unlike MoDIL, however, it is non-trivial to 
reliably distinguish between noise and indel distribution because mixtures 
of distributions will be unbalanced under low minor allele frequency for 
indels. To address the problem we develop a Bayesian network that takes 
advantage of the structure of the matepair data. Specifically, we use  
priors to explicitly model each individual as homozygous or heterozygous, 
and compute the expected minor allele frequency at each location along the 
chromosome. We use MoGUL to identify variants in the 1000 Genomes 
data and simulated genotypes, and demonstrate that it allows for the 
identification of indels > 30 bases for MAF > 0.04, while indels as small as 
20 bases can be identified for MAF > 0.06.  
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A number of studies investigating the clinical utility of genetic variants 
associated with complex disorders have illustrated the limitations and 
potential benefits of using genetic information in risk prediction for 
complex traits. The focus of this study was to assess the clinical validity of 
previously published genes associated with alcohol dependence (AD) in 
predicting risk for AD in an independent sample. The predictive ability of 
these genes was compared to family history. Using the Collaborative Study 
on the Genetics of Alcoholism (COGA) genome wide association study 
(GWAS) sample, we performed receiver operating characteristic (ROC) 
curve analysis to estimate the ability of a panel of SNPs to correctly classify 
cases and controls for DSM-IV AD. Specifically, sum scores of risk alleles 
were generated for a panel of 24 semi-independent SNPs, covering 15 genes 
that had reported associations with alcohol dependence in the COGA 
family-based association sample. We identified a subset of individuals 
consisting of 627 cases and 454 controls from the COGA GWAS sample 
that were not part of the original family-based association sample and 
performed ROC analysis for the sum scores in this subset. These analyses 
did not result in significant discriminative ability for the sum scores; the 
area under the ROC curve (AUC) was 0.498 (95% CI = 0.463, 0.533, p > 
0.05), suggesting that the SNPs are not predicting better than chance. The 
presence or absence of family history for AD was a better classifier of case 
control status in the COGA sample, with an AUC of 0.686 (95% CI = 
0.654, 0.718, p < 0.001). This study shows that these SNPs currently have 
limited clinical utility and illustrates the need for further expansion of 
prediction panels for a complex disorder that encompasses both 
environmental and genetic risk factors of small effect such as AD. 
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Second generation sequencing technologies have enabled personal 
genomics by providing high read-depth sequencing coverage. Despite the 
fact that the sequencing cost continuously decreases, it is still not possible 
to sequence all individuals to high depth. We aim to enable personal 
genomics via extremely low coverage whole genome sequencing 
approaches. However, as the overall read-depth coverage decreases, the 
genotype quality is compromised by errors in each of the sequencing, 
mapping and allele sampling processes. Fortunately, these caveats can be 
accounted for by statistical methods and consideration of population 
genetics information. We devised an approach utilizing existing information 
from various publicly available large-scale population sequencing projects, 
such as the 1000 Genomes Project, to reliably determine personal genotypes 
at lower coverage in a de novo individual sequencing data set. 
 
Our pipeline integrates population genetics principles, and can be applied to 
genotype calling in low-coverage whole genome sequencing data produced 
from multiple platforms (SOLiD, Illumina and Roche 454). We first detect 
single nucleotide polymorphism (SNP) sites by a likelihood ratio index 
which compares a population-based SNP model against a null model for 
basal distribution at every base pair. And then we apply an iterative SVD 
algorithm to perform genotyping. In addition, the pipeline includes a well-
calibrated module for the SOLiD data filtering, which allows us to reduce 
80% of the raw sequencing errors at the cost of only 10% of the overall 
read-depth. We tested our pipeline in the 1000 Genomes low coverage 
sequencing data. And the results suggest that (1) our method has high 
specificity (~93% Sequenom validation rate, ~52% dbSNP confirm rate) in 
SNP detection than the current version of the publicly released SNPs (i.e. 
March 2010 release, ~88% Seqenom validation rate, ~48% dbSNP confirm 
rate); (2) our method is highly accurate in SNP genotype determination with 
or without HapMap information (97.5% and 97% HapMap concordance 
rate respectively); (3) our informatics pipeline has both low CPU and disk 
cost. Our approach holds promises to further reduce the cost of personal 
genomics, and is computationally feasible.  
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The rapidly decreasing cost of sequencing makes it inevitable that 
individuals will soon be able to get detailed genomic information (probably 
in the form of whole genome sequences) for an affordable price. Early 
adopters will purchase their genomes out of curiosity, and out-of-pocket. 
Then patients needing a conventional genetic test – and their health 
coverage payors– will find it nearly as inexpensive to order a full genome as 
a test of a few genes. Finally, as the price sinks, broad and deep genomic 
information will become standard of care for all patients.  
 
The problem will be figuring out how to handle the enormous amount of 
genomic information that this will supply. Building on a publication based 
on examining one person's whole genome sequence (Kelly E Ormond, et 
al., Challenges in the Clinical Application of Whole-Genome Sequencing, 
THE LANCET, (2010) 375:1749-51), this talk will examine some of those 
challenges – in the informed consent process, in the clinical analysis of the 
genomic data, in physicians' obligations, and in educating patients about the 
results – and will suggest some ways of maximizing the benefits, and 
minimizing the risks, of these technologies. 
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The widespread use of chromosomal microarray analysis (CMA) has been 
highly successful and may be the greatest benefit to date of the Human 
Genome Project. CMA has greatly improved the ability to identify causative 
genetic deletions and duplications associated with intellectual and 
developmental disabilities and with birth defects. Approximately 20% of 
serious disabilities are caused by deletions and duplications that are 
detected by CMA. Some of these mutations are highly penetrant and some 
are less penetrant. CMA is also contributing novel insights into the etiology 
of behavioral disorders such as autism and schizophrenia. There are 
multiple ethical, social, moral, and legal issues arising from CMA. First, 
some genotypes such as deletion of CHRNA7 appear to be associated with 
intellectual disability, autism, schizophrenia, perhaps antisocial behaviors, 
and with incomplete penetrance. Diagnosis of these genotypes can lead to 
stigmatization of children and adults who may or may not ever develop 
antisocial behaviors. Second, CMA can be used for prenatal diagnosis to 
detect ~20% of serious developmental disabilities. This raises questions 
about whether such prenatal diagnosis should be offered for all pregnancies 
by private and governmental health care programs, and whether termination 
of affected pregnancies might be minimally or widely utilized. Third, single 
nucleotide polymorphism (SNP) arrays detect regions of absence of 
heterozygosity occurring through identity by descent related to 
consanguinity. SNPs are being added to array platforms that previously 
lacked SNPs so that the majority of children with disabilities will be 
routinely tested with SNP arrays. When about one quarter of the genome 
across all chromosomes shows absence of heterozygosity, the most likely 
interpretation is that the individual is the offspring of incestuous parentage. 
No parental samples are needed to detect these circumstances. Such 
individuals have a very high incidence of developmental disabilities. These 
cases raise significant legal issues particularly if a minor is sexually abused 
by a family member. 
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The Department of Pathology, Beth Israel Deaconess Hospital working with 
a consortium of stake holders from health care, government and private 
industry are incorporating whole genome sequencing into best practice 
pathology (1). Much like the dramatic shift in biomedical science, whole 
genome sequencing, expression profiles and other high-throughput 
clinically relevant technology will create a post-genome paradigm in health, 
prevention, and personalized medicine. However, this paradigm shift will 
not take place until medical education and training has shifted to a post-
genome perspective (2). Our initiative started with a post-genome training 
program for pathology residents (3). The impact of this initiative has 
become the fulcrum to a pathology-wide ‘call to action’ to address those 
barriers to full incorporation of genetics and high throughput molecular data 
and information processing into current best practice pathology. Our efforts 
now include technology to process and integrate personal genomes into the 
EHR, redefining regulatory management of whole genome sequencing in 
the clinical laboratory, reimbursement, and creating a robust clinical 
business model for post-genome pathology practice. These and parallel 
efforts though difficult, disruptive and time consuming will catalyze the 
adoption and widespread implementation of the post-genome competency 
required to fully capture the value of whole genome information and 
thereby position the discipline of pathology to lead rather than follow in the 
coming era of personalized medicine.  
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With the rapidly decreasing cost of sequencing, it has become feasible to 
perform complete exome or genome sequencing as part of research studies 
and in a limited number of clinical situations. The interpretation of these 
data remains a challenge but will become more robust with the availability 
of additional reference genomes, more extensive annotation of sequence 
variants, and with computational methods to analyze the data. In 
anticipation of when complete genomic sequence will be routinely 
available, we should begin now to anticipate the ethical issues that will 
arise. These issues include: 1) What data should be returned to patients 
requesting clinical testing to identify a single gene disorder and will 
“incidental” genetic findings be reported? 2) What obligation do clinical 
testing laboratories have to comprehensively identify all disease associated 
variants if such incidental findings are to be reported? What clinical criteria 
will be used to determine what is reported? Will there be an ongoing 
responsibility to revise the data interpretation as additional scientific data 
become available? 3) What results should be reported to minors undergoing 
such clinical testing? 4) What results should be reported to research 
participants and should research participants be specifically consented for 
comprehensive genome analysis if results will be reported? 5) What is the 
psychosocial impact on patients and families in appreciating their genetic 
susceptibility to diseases on such a large scale and are there differences in 
the impact regarding neuropsychiatric/behavioral conditions? In some 
cases, policies by NIH and other scientific and medical organization would 
be helpful to guide others who are well meaning but inexperienced with 
these issues. 
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I will present initial results from DNA sequencing of a family of four. 
Scientific analysis of the data has focused on meiotic recombination and 
copy number variation. Medical analysis has focused on compound 
heterozygosity in genes of the blood coagulation pathway. I will also 
describe efforts to help build an open access database linking DNA 
mutations with published clinical results. 
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Next generation sequencing technology has heralded a new era in 
biomedical research. In the case of Cancer Genetics, it is now feasible 
sequence the genomes of both normal and tumour tissues and define the 
complete repertoire of somatic aberrations arising in individual patients. 
Creating such surveys in large cohorts provides opportunities to redefine 
disease taxonomy, discover new prognostic markers, create new strategies 
for cancer surveillance and the potential to improve therapeutic 
intervention.  
The International Cancer Genome Consortium (ICGC) is an coordinated 
program to systematically sequence the cancer genomes / transcriptomes 
and methylomes of 25,000 patients over the next 5 years. The Australian 
ICGC program was initiated in July 2009 and is focused on matched 
normal/tumour whole genome/transcriptome/methylome sequencing of 375 
Pancreatic and 125 Ovarian Cancers. We have commenced a systematic 
analysis of matched normal and tumour genomes (paired end whole genome 
and exome sequencing) transcriptomes (deep stranded RNAseq and 
miRNAseq) and methylomes (Methyl Capture seq). This has been used to 
catalogue genome wide variation and somatic mutation. We have studied 
also the dynamics of transcriptional complexity driven by tumorigenesis 
and looked for cancer miRNA-mRNA networks tumours. These surveys of 
genomic damage and transcriptome dynamics are being integrated to 
develop models of the underlying driving mechanisms driving individual 
cancers. 
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Clear-cell renal cell carcinoma (ccRCC) is the most common malignant 
kidney tumor, exhibits an unusual clinical behavior, and is resistant to 
chemotherapy. A recent analysis of 3,544 protein-coding genes showed that 
genes frequently mutated in other tumor types were not mutated in ccRCC 
and the genes involved remain unknown. We have sequenced the genome 
of a ccRCC (and normal DNA) at 35x. 35 non-synonymous and 4 splice site 
mutations were found. 34 of 35 mutations examined were confirmed by 
capillary sequencing including a mutation in the VHL gene, the only gene 
known that is commonly mutated in ccRCC. The majority of genes 
identified have not been previously implicated in cancer. Studies were 
extended to examine a primary xenograft growing orthotopically in a 
mouse, in which 94% of the mutations were present, as well as a panel of 79 
ccRCCs. Importantly, a splice site mutation was found in a critical negative 
regulator of mTORC1, a complex that is inhibited by the sirolimus prodrug 
and FDA approved drug temsirolimus. While the mutation, which was 
accompanied by LOH, did not alter the ORF, reconstitution experiments in 
knockout cells showed that unlike the wild-type protein, the mutant protein 
was unstable resulting in inappropriate mTORC1 activation. Constitutive 
mTORC1 activation was demonstrated in both the primary tumor and the 
xenograft. Treatment of the xenograft with sirolimus (administered in a 
regimen that mimicked drug exposures in humans) caused tumor regression 
in xenografts. Importantly, mTORC1 inhibitors similarly resulted in 
prolonged disease stabilization in the patient. We believe this is the first 
instance of a cancer genome sequenced in a CLIA certified and CAP 
accredited laboratory and our work illustrates how genome sequencing 
coupled with functional analyses and studies in xenografts provides insight 
into the mechanism of ccRCC development and represents a paradigm for 
disease translation. 
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Ninety-five percent of Acute Promyelocytic Leukemia (APL) patients have 
a reciprocal translocation between chromosomes 15 and 17 in their 
leukemic cells. Typically, the translocation generates two fusion proteins, 
PML-RARA and RARA-PML. PML-RARA initiates APL in mouse 
models, but is not sufficient to cause disease; additional cooperating 
mutations are required for full blown leukemia. Patients with APL achieve 
significantly better outcomes when ATRA is combined with conventional 
AML chemotherapy approaches, during remission induction and post-
remission therapy. Only PML-RARA positive APL patients respond to 
ATRA, however, so defining the presence of the PML-RARA fusion 
protein rapidly after diagnosis is important. The diagnosis of t(15;17) APL 
is achieved by karyotypic analysis of leukemia cell chromosomes, and 
confirmed by FISH using a set of defined probes to identify the 
translocation. However, a subset of patients with morphologic APL cases 
have normal cytogenetics and no evidence of the 15;17 translocation by 
FISH. These patients represent a diagnostic and therapeutic dilemma.  
Recently, we encountered a 39 year old female with morphologic APL but 
without cytogenetic evidence for t(15;17). In particular, FISH studies 
revealed no evidence for a PML-RARA fusion, but did reveal evidence for 
an RARA-PML fusion. For reasons stated above, we felt it important to 
establish whether the t(15:17) did exist. A complete remission was 
established without the use of ATRA, but in the absence of a proven PML-
RARA fusion, it was unclear whether including ATRA in subsequent 
therapy would be of benefit. In order to resolve this issue expeditiously to 
guide therapeutic decision-making, we decided to use whole genome 
sequencing on the Illumina platform. Using BreakDancer and validation by 
PCR plus sequencing, we identified a novel transposition mechanism that 
generated a classical bcr3 fusion of PML and RARA. The fusion mRNA 
between PML and RARA was directly demonstrated. Based on these data, 
the patient was started on ATRA as part of consolidation therapy. Now, 
additional APL cases with normal cytogenetics are being examined for 
evidence of this insertional mechanism of fusion gene generation. This case 
demonstrates the clinical use of whole genome sequencing to rapidly solve 
a diagnostic dilemma that led to the choice of an appropriate therapy for a 
patient with a potentially lethal leukemia syndrome. 
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We have investigated the utility of massively parallel sequencing 
approaches for the characterization of a rare tumor type, a adenocarcinoma 
of the tongue, before and after treatment with sunitinib and sorafenib. We 
sequenced DNA from peripheral blood, resected tumor material, initial 
metastases present in the lung and also recurrent metastasis from in a 
growing skin nodule on the neck. We also sequenced cDNA prepared 
peripheral blood and from the pre and post treatment metastases. In the pre-
treatment tumour, we identified 5,679 genes within copy number 
amplicons, 409 genes exhibiting increased expression relative to unrelated 
tumors and 4 somatic protein-coding mutations. Proteins targeted by the 
receptor tyrosine kinase inhibitor sunitinib were highly correlated to 
amplified, highly expressed or wild type gene products. Consistent with 
these observations the subsequent administration of sunitinib was associated 
with stable disease within four weeks of treatment, lasting 4 months, after 
which his lung lesions began to grow again. He was then put of sorafenib 
and sulindac and enjoyed disease stabilization for an additional 3 months 
after which his cancer began to progress and new lesions were identified in 
the lung, the primary site in the tongue and in a skin metastasis in the neck. 
The tumour recurrence was determined to possess 7,288 genes within copy 
number amplicons, 385 genes exhibiting expression changes relative to the 
cancer panel and 9 new somatic protein coding mutations, which included 
the four observed in the pre-treatment sample. The observed mutations and 
amplifications were found to be consistent with resistance to sunitinib 
arising through activation of the AKT pathway. Our results provide insight 
into how genomic and bioinformatic strategies can predict treatment 
response, may aid in clinical decision making and identify the mode of drug 
resistance arising within cancer patients. 
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Despite the well-funded, 40-year-old war against it, cancer still continues to 
kill half a million individuals only in the USA. Treatment regimens, which 
traditionally include blockbuster drugs (drugs for a large population of 
patients), are not effective in the majority of patients. Fortunately, recently, 
the personalized medicine approach promises more clever treatment 
strategies. It could provide optimized therapies to patients with specific 
genetic profiles. However, this approach also has some prerequisites: 
 
- A comprehensive view of all the alterations that can take place in different 
cancer types/subtypes. 
- Integrative methodologies to detect the relationships among alterations to 
gain insights into the underlying biological processes 
 
In our group, we have been developing the necessary technologies to 
address these two main needs. We have recently released IntOGen. It is a 
cancer-oriented, discovery tool, which collates, annotates and analyzes 
alterations implicated in a large array of cancers. Taking into account the 
heterogeneity of cancer, IntOGen aims to comprehensively catalogue 
tumourigenesis-related genes/processes common to a number of cancer as 
well as those specific to different cancer types. 
 
We have also created Gitools, which facilitates the analysis of high-
throughput genomic data. It comprises the innovative methods and intuitive 
visualization systems to integrate different alterations taking place in the 
same cancer. In addition, Gitools enables the analysis of the cancer sample 
in question in comparison with the wealth of cancer-related information 
from IntOGen. 
 
We are now remodeling IntOGen to store, analyze and visualize next 
generation sequencing data from cancer samples coming from ICGC. 
IntOGen is being used for the analysis and visualization of Chronic 
Lymphocytic leukemia data from the Spanish ICGC project. 
 
We believe IntOGen and Gitools will facilitate the analysis of personal 
genomic information in the context of cancer. 
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Rare inherited forms of cancer with high penetrance such as Li Fraumeni 
syndrome, retinoblastoma, and HNPCC have been recognized for decades. 
Germline variants for loci such as BRCA1/2 have also provided compelling 
evidence that inherited variation in cancer susceptibility accounts for at least 
5-10% of breast cancer cases. We are screening our next generation 
sequencing data for evidence of germline variation that could be involved in 
cancer. First, we identify germline variants that are likely to abolish gene 
function: small indels, nonsense or splice-site variants. Then, in the tumor, 
we identify potential ‘second-hits’ by screening for i) genes found 
recurrently mutated in the Catalog of Somatic Mutations in Cancer 
(COSMIC) database, ii) loss of heterozygosity, or 3) presence of a somatic 
mutation in the normal allele in the tumor. In 34 ovarian serous 
cystadenocarcinoma samples from the TCGA consortium, this approach 
identified indels in 265 genes. Thirty-four genes in indels were found in 
COSMIC and six genes exhibited a pattern of sequence coverage suggesting 
LOH in the tumor: BRCA2, PIK3C2G, ABCA10, PRKRA, ATP7B and 
ENPEP. BRCA2, a known germline mutation would be expected from a 
screen like this in ovarian cancer. In 14 hepatocellular carcinoma samples, 
this approach identified four genes, including MAP1B, GEN1, MAP3K14, 
and PIK3C2G that was also identified in our ovarian cancer subjects. We 
are investigating further to validate the observed genetic variation, and 
designing genetic follow-up experiments to determine the allele frequencies 
in normal populations and verify the possible role of these genes in the 
disease. 
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Cancer develops not only as a result of genetic mutations and genomic 
rearrangements, but also as a consequence of numerous epigenetic 
alterations, including extensive changes in the distribution of DNA 
methylation throughout the genome. DNA methylation changes contribute 
directly to cancer by transcriptional silencing of tumor-suppressor genes 
through promoter CpG island hypermethylation. As is the case for genetic 
alterations, some epigenetic events help to drive oncogenesis, while others 
represent non-functional passenger events. Broad epigenomic analysis of 
human tumors can reveal relationships between large numbers of epigenetic 
events and can provide insight into the mechanisms underlying concerted 
epigenetic change. Genomic loci targeted by Polycomb Group Repressors 
in embryonic stem cells, and involved in cellular differentiation are 
predisposed to become methylated in cancer cells, suggesting that an 
epigenetic block to cellular differentiation may sometimes be an initiating 
event in carcinogenesis. The very strong associations between distinct 
epigenetic subtypes, such as CpG Island Methylator Phenotypes (CIMP) 
and specific somatic genetic events, such as BRAF mutation in colorectal 
cancer and IDH1 mutation in glioblastoma multiforme are consistent with 
an early role for DNA methylation alterations, providing a favorable 
cellular context for the subsequent somatic mutation. For example, 
colorectal CIMP results in silencing of IGFBP7, which has been implicated 
in mutant BRAF-induced senescence pathways. Advances in technology 
provide opportunities for personalized clinical applications of epigenetics. 
These include the highly sensitive and specific detection of DNA 
methylation abnormalities in the serum and plasma of cancer patients by 
Digital MethyLight, while next-generation sequencing technologies provide 
single-basepair resolution DNA methylation maps by whole genome 
shotgun bisulfite sequencing.  
 
 68 
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We used next generation sequencing of small RNA cDNA libraries derived 
from a range of cell types and tissues versus a chemically synthesized 
microRNA (miRNA) library to study post-transcriptional modification of 
mature miRNAs. We found that such modification, which occurs primarily 
at the 3’ end, is a common and physiologic phenomenon that shows 
selectivity for subsets of microRNAs, with some miRNAs being nearly 
always modified from their canonical form and others never being 
modified. Modifications are predominantly additions of A or U, are seen 
across tissue types, in both normal and cancer tissues, and are seen across 
species. Additions occur to both canonical miRNA sequences and to 
miRNAs that show evidence of initial trimming back by one or two 
nucleotides from the 3’ end. Given that 3’ adenylation/uridylation in plants 
has been shown to affect miRNA stability and that the liver-specific 
miRNA miR-122 is regulated by post-transcriptional modification in 
mammals, our global analysis suggests that 3’ post-transcriptional 
modification may be a broadly used mechanism for both increasing 
complexity of and regulating the miRNA transcriptome. 
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Personal genomics will utilize a multi-modal approach where dataset from 
various genomic high-throughput technologies will be correlated together to 
derive bio-medical significance. In the current study, we have correlated 
dataset from three technologies including 120 Affymetrix SNP6.0 array 
(sub-population from Indian subcontinent), custom Homo sapiens 44k Gene 
expression array from Agilent and whole genome data from Genome 
analyzer II from Illumina. After initial QC and removal of irrelevant 
markers using Minor allele frequency (MAF) and Hardy-Weinberg 
equilibrium (HWE) p-value, selected marker validation was performed 
across platforms to confirm the reproducibility of results. High concordance 
of SNPs (99.53%) was observed across platforms. Functional variations 
were called (nonsynonymous SNP and Indels leading to functional changes) 
from whole genome sequencing (using Burrows-Wheeler Alignment) and 
were validated using gene expression data. Functional loss suggested by 
whole genome sequencing was not complemented by gene expression 
results. It was not possible to determine the altered transcript through gene 
expression, therefore, we are currently carrying out RNAseq analysis. 
However, most of the 247 genes that showed functional modification in 
whole genome sequencing have been reported to have multiple transcripts 
in public repositories. Further, disease risk prediction in terms of allele 
representation was also explored in multiple databases (OMIM, dbGAP and 
PharmGKB) and is complemented by gene expression data. This study 
indicates the importance of multi-modal analysis of genomic data arriving 
at a definitive conclusion with high significance. 
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Personal genome sequencing is providing the catalog of genetic variation 
across phenotypically diverse human populations and identifying numerous 
variants between individuals with and without disease. However, it is still a 
significant challenge to identify those sequence variants with functional 
significance that contribute to a particular phenotype, especially for variants 
that fall into the vast intergenic regions of the genome. As part of the 
ENCODE Project, we have used a combination genomic assays to identify 
functional non-coding regions of the genome. By identifying regions bound 
by transcription factors, we are striving to identify intergenic sequence 
variants that alter gene regulation. By measuring the influence that genetic 
variants have on transcription factor binding and gene expression in an 
individual with a completed genome sequence in the context of a family 
trio. By measuring functional events with DNA sequencing-based 
approaches in the individual, we have observed allelic biases in these events 
that are likely driven by local cis-acting sequence variants.  
By using RNA-seq and ChIP-seq, we measured gene expression, occupancy 
by RNA Polymerase 2, and the binding sites of 25 sequence-specific 
transcription factors in an individual’s lymphoblastoid cell line. We aligned 
the sequence reads from the functional assays to the individual’s genome 
sequence obtained by the 1,000 Genomes Project, which allowed us to 
measure allelic biases in both gene expression and transcription factor 
occupancy. More than 10% of genes have allele-biased expression (ABE), 
with allelic specificity ranging from monoallelic expression to more subtle 
differences between the abundance of each allele. Transcription factor 
binding appears more constrained; only 1% of transcription factor binding 
sites exhibit allele-biased occupancy (ABO). We used personal genome 
sequences from the individual’s parents to directly associate biases in TF 
occupancy with biases in gene expression on the same haplotype, providing 
mechanistic insight into the effects of regulatory sequence variants. We then 
performed the same functional assays in the subject’s parents to assess the 
penetrance of cis-regulatory variants. This study demonstrates that 
performing genome-wide functional genomic assays in individuals with 
complete genome sequences helps determine the functional significance of 
non-coding variants, which will be helpful for identifying genetic variation 
associated with phenotypes and disease.  
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RNAseq is a powerful method for transcript analysis as it enables the digital 
quantification of all unique mRNAs occurring within a sample. The 
NanoString technology is conceptually similar to RNAseq in providing a 
digital method for mRNA quantitation by the use of colour-coded molecular 
barcodes and single molecule imaging to detect and count multiple unique 
transcripts in a single reaction.  
 
We have generated NanoString profiles of 30 genes in samples where 
biological replicates have subsequently been profiled by RNAseq. We show 
that the NanoString and RNAseq data types are highly correlated across a 
wide range of expression levels (6 orders of magnitude) suggesting that 
digital methods of mRNA counting are robust and generate reproducible 
data.  
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DNA methylation is a dynamic mark in the genome that is essential for cellular 
differentiation and reflects the functional state of a cell. The role that genetics 
plays in determining DNA methylation patterns remains largely unknown. To 
study the influence that DNA sequence variation has on DNA methylation we 
performed reduced representation bisulfite sequencing (RRBS) on DNA 
extracted from leukocytes from 6 members of a three-generation family. RRBS 
allows us to accurately quantify the percentage of molecules with methylation at 
900,000 CpG positions across the genome. We can associate the percent 
methylation at each CpG with adjacent SNPs in the same molecule to identify 
allele-specific methylation (ASM).  
 
We identified ASM at 5.7% of all heterozygous SNPs in the dataset, 
representing between 1,699 and 2,088 instances in each family member. We 
used inheritance patterns to determine if these events are the result of parent-of-
origin imprinting or DNA sequence variation. We found that the vast majority 
of ASM (>92%) is associated with a particular sequence variant as opposed to 
being associated with the sex of the parent-of-origin. To determine if these 
genotype dependent ASM events were associated with the same SNPs in 
unrelated individuals we performed RRBS on primary leukocytes and a 
lymphoblastoid cell line from individuals outside of the family. We found that 
75% of the genotype dependent ASM events found in the family were 
replicated, which indicates that even in different genetic backgrounds the 
genotype is associated with altered DNA methylation.  
 
We found that ASM events are under-represented in CpG islands, enriched in 
intergenic regions, and more often exist in regions of low evolutionary 
conservation. Even though they are generally not found in functionally 
constrained regions, some ASM events are associated with gene expression 
differences. By performing RNA-seq and RRBS on the same lymphoblastoid 
cell line, we found that 25% of genes harboring allele-specific methylation in 
their promoter exhibited allele-specific gene expression, which is twice as many 
as expected by chance. Overall, our results demonstrate that genomic sequence 
variation can significantly influence DNA methylation. 
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Using whole-genome sequence data from a family of four, we recently 
estimated the human mutation rate to be 1.1 x 10-8 per base pair per 
generation (95% CI = 6.8 x 10-9 – 1.7 x 10-8). Nearly 34,000 potential new 
mutations were identified initially by high-throughput sequencing, and each 
of these was resequenced to eliminate false positive signals. This reduced 
the number of verified new mutations in each diploid genome to 
approximately 70. As expected, the mutation rate is substantially elevated 
for CpG dinucleotides, and the transition-transversion ratio is 2.3. Our 
mutation rate estimate is lower than a previous estimate based on 20 
protein-coding genes (1.7 x 10-8); we suggest that the latter figure may be 
inflated by ascertainment bias for loci with relatively high mutation rates. 
Our mutation rate estimate is substantially lower than the commonly used 
phylogenetic estimate of 2.5 x 10-8 per base pair per generation. The 
difference in these figures can be reconciled by assuming a human-
chimpanzee divergence time of 6-7 million years ago and by assuming a 
relatively large effective population size of the population ancestral to 
humans and chimpanzees (40,000 – 148,000). We discuss the implications 
of this new mutation rate estimate for evolutionary and biomedical studies.  
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Rare coding variants in the human genome have been implicated in the 
development of a multitude of Mendelian diseases. Recent studies of large 
scale whole genome and targeted sequencing have shown that rare variants 
are significantly more common than originally thought. Our ability to 
distinguish disease causing mutations from benign mutations in targeted 
sequencing studies is thus hampered by the prevalence of rare non-
synonymous SNPs, especially for dominantly inherited diseases. 
 
We show the efficacy of two approaches for discovering candidate 
mutations for dominant diseases. First, sequencing multiple affected and 
unaffected individuals in a single pedigree and second, sequencing multiple 
unrelated individuals. In the former case, a single identical mutation must 
be shared among all the affected individuals and we show in a single 
pedigree with Left Ventricular Non-Compaction (LVNC), that sequencing 3 
affected and 3 unaffected individuals yields ~30 candidate mutations. In the 
latter case, mutations are only required to affect the same gene in different 
pedigrees and we demonstrate a hybrid approach where we sequence 2 
affected individuals from 2 unrelated families suffering from Osteogenesis 
Imperfecta. This approach yields ~16 candidate genes. 
 
Lastly we show the value of large scale whole exome sequencing projects in 
discovering rare, nonsynonymous, non-disease causing mutations. Currently 
we have discovered over 120,000 singleton, coding non-synonymous 
variants which have not been described in either the 
Thousand Genomes project or in dbSNP. This collection is invaluable for 
eliminating candidate mutations from consideration in disease discovery, 
and typically removes an additional 50-75% of mutations over dbSNP and 
Thousand Genomes. 
 
Our work outlines strategies for discovery of candidate mutations for 
autosomal dominant diseases and highlights the importance targeted 
sequencing across large, phenotypically-normal, populations. 
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Discovery of the genetic etiology of Crohn disease represents a paradigm 
for polygenic traits in humans with over 30 replicated disease genes/loci 
identified mostly by genome-wide association studies (GWAS). However, 
not more than 20% of the cumulative genetic variance can be explained by 
the findings made. Gathering knowledge on entire individual disease 
genomes is a logical advancement of GWAS as it includes rare and 
potentially causative variants “hidden” on common haplotypes.  
For this benchmarking study, a Falk-Rubinstein trio with an extreme 
phenotype was selected, i.e. early, severe onset, in which we expect a 
stronger and a more oligogenic genetic etiology. Both parents never 
suffered from relevant intestinal symptoms, whereas the affected child was 
diagnosed with therapy refractory Crohn´s disease at the age of 2 years. 
Genome sequencing of the 3 individuals was carried out on an Applied 
Biosystems SOLiD™ System. we analyzed approx. 0.8-1 billion shotgun 
mapped reads from 50+25 bp paired end libraries and 0.6 billion 50+50bp 
mate paired reads for each of the individuals. With a minimum mapped total 
throughput of 31 Gb for each individual run, over 96% of the reference 
genome was covered with at least one uniquely placed pair of reads in each 
of the libraries. The genome data sets resulted in 3.06 to 3.18 million SNP 
calls with high confidence, approx. 10% of which are not annotated in 
current databases. Categorization of the SNPs in relation to functional 
elements in the genome identified app. 8000 SNPs in each of the individuals 
as missense SNPs. We utilized the pedigree structure to prioritize 613 SNPs 
which were annotated for having a putatively functional effect and for 
which the child was homozygous while the parents were heterozygous for 
the mutation. The individual genomes are related to corresponding RNAseq 
data from peripheral blood mononuclear cells and intestinal tissue resulting 
in a comprehensive map of expression levels, alternative splicing and allelic 
imbalance.  
In conclusion, we present the first study aiming for the extraction of the full 
genetic variability in a disease trio and utilizing this data together with 
genetical genomics analyses by RNAseq as a basis for personalized 
understanding of the genetic variants that cause human disease. The 
potential success of a genome-guided choice of individual experimental 
approaches will be the ultimate test for the interpretation of disease 
genetics.  
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Massively parallel sequencing has allowed broader interrogation of 
genomes for variants that cause disease. Continuing improvements now 
allow whole human genome sequencing in a relatively short period of time. 
Targeted sequencing requires fewer bases than a whole genome, and 
therefore allows more targeted samples than whole genome samples. We 
have compared coverage of the CCDS exome in NA18507 (HapMap 
Yoruba) using three different exome capture kits. We find that genotype 
sensitivity (% of the CCDS regions covered with high-quality genotype 
calls) is similar among all methods: 86%-88%. In comparison, previously 
reported 30x whole genome coverage of the CCDS regions in NA18507 
was ~73%. We have also compared a more recent 60x whole genome 
sequence of a ClinSeq™ individual with exome capture. 60x whole genome 
sequence covered 86% of the CCDS using 192Gb total sequence, whereas 
exome capture covered 89% with 6.7Gb total. Both methods showed 
>99.9% overall concordance with genotype chip calls. 
We have implemented a secondary analysis pipeline to realign reads using a 
gapped aligner, cross_match, and to call genotypes using a Bayesian based 
program, Most Probable Genotype (MPG). Genotypes are then annotated 
for coding status and potential detriment using CDPred. We have also 
developed a graphical Java tool, VarSifter, to view, sort, and filter the 
resulting data, allowing investigators to focus on interesting variants. Using 
these tools, we have sequenced and analyzed more than 80 exomes as part 
of the ClinSeq™ program. 
We have performed both whole genome shotgun and exome sequencing on 
a ClinSeq™ individual at high risk for atherosclerosis. To get the highest 
coverage, we have merged the two data sets, resulting in 94.9% genotype 
coverage of the CCDS. Using our analysis tools, we identified 3,719,419 
total variants, 22,264 of which were coding. We have examined the 
variants, and have limited the list by removing variants observed in 8 
previously published HapMap samples, by focusing on non-synonymous 
single-nucleotide variants and frame-shifting deletion/insertion variants, and 
by examining variants within a linkage region. Many variants fit these 
criteria, and we are currently evaluating which are most likely to be 
causative. 
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Ion Torrent Systems has developed a DNA sequencing system that directly 
translates chemical signals into digital information on a semiconductor chip. 
This approach leverages a trillion dollars of investment from the 
semiconductor industry taking advantage of existing state-of-the-art chip 
fabrication technology, and the entire semiconductor design and supply 
chain. Unprecedented scalability and cost reduction result from decades of 
Moore's Law advances in semiconductor technologies that are brought to 
bear within a few years for DNA sequencing. 
 
Ion Torrent sequencing takes place in semiconductor microchips that 
contain sensors which have been fabricated as individual electronic 
detectors, allowing one sequence read per sensor. Current configurations 
have 1.5 million sensors in a 1 cm2 chip, with proof of principle to enable 
densities over 100 million sensors per chip. 
 
The sequencing chemistry itself is remarkably simple. Native nucleotides 
are incorporated into the growing strand by native DNA polymerase. As a 
base is incorporated, a direct electrical measurement of the incorporation 
event is made and the sequence is read out directly into the digital domain. 
Thus, sequencing is direct, efficient, and massively parallel, requiring no 
specialized reagents and no optical systems. Using native DNA chemistry 
with real time detection enables run times to be very short, on the order of 
an hour or two with a throughput on the order of 100 Megabases per hour. 
We will present data and describe metrics from the adenovirus and E. coli 
genomes. 
 
The Ion Personal Genome Machine (PGM™) sequencer, which will be 
commercially available in 2010, provides a powerful tool not only for 
research, but also for diagnostics development. The sequencer is 
manufactured at a plant that is FDA Registered, California licensed and ISO 
13485 Certified. With a manufacturing facility that has certifications, 
quality systems and documentation controls already in place, the Ion 
Torrent sequencer is well-positioned for diagnostic applications. 
 
The simplicity of a semiconductor chip that reads itself means that desktop 
and portable instruments will be available at a fraction of the cost of other 
next-generation instruments; the use of standard reagents, low reaction 
volume and high data density keep reagent costs low; computational 
infrastructure and staff support requirements are modest; finally, the short 
run time supports fast research cycle times and promotes the use of 
sequencing in everyday research and diagnostic application development.  
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A single molecule DNA sequencing technology has been built onto the 
surface of a ~ 10 nm quantum-dot nanocrystal. A specially constructed 
DNA-polymerase-quantum-dot nanocrystal conjugate has been developed 
that as an “exchangeable-reagent”, allows for single molecule sequencing to 
be performed with tunable ultra-long read-lengths and tunable high-
accuracies. Five-color fluorescence resonance energy-transfer technology 
(FRET) is utilized for DNA sequence detection, in which signals from the 
quantum-dot labeled DNA polymerase plus 4 DNA-base-specific acceptor 
dyes are simultaneously detected. Acting as the FRET donor, the Qdot™-
polymerase generates a correlated “photon-dip” for every inserted base 
(termed the “quantum-correlation-signal”), allowing for more accurate base-
calling. Because the sequencer is not physically bound to any solid 
substrate, it can be exchanged (like a reagent) during mid-sequence runs, 
effectively replacing damaged non-functioning polymerases mid-reaction. 
Each exchange cycle lengthens the effective read-length of the sequencer. 
In this manner, the read-length can be continuously extended without 
“gaps”. Expanding upon this flexibility, after sequencing a particular length 
of DNA, the newly synthesized strand can be selectively removed. The 
original genomic DNA strand is then re-primed, Qdot™-polymerase 
sequencers are rebound, and the identical genomic DNA strand can be 
sequenced again, greatly increasing the net accuracy (and not requiring 
circularization of genomic templates). In combining these features, the 
desired accuracy and read-length can be “tuned” by adjusting the number of 
reagent exchange cycles. Because each sequencing reaction can be 
completed in minutes, multiple exchange experiments can be performed per 
sequencing hour. Precisely engineered sequencing-grade Qdot™ 
nanocrystals are smaller than current commercially available materials (to 
increase FRET signals), and have an exctinction coefficient ~100X greater 
than organic-dyes, allowing for very low levels of excitation power to be 
used while sequencing, yielding an environment more biologically 
favorable to polymerase activity and template integrity . Examples of real-
time sequencing of homopolymeric, patterned, and complex templates at 
rates of ~ 3 base-pairs per second will be shown. 
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Next-generation DNA sequencing technologies are enabling the sequencing 
of numerous human genomes. However, most of these technologies produce 
relatively short reads that complicate analysis and assembly of highly 
repetitive regions of the genome. Paired end, or mate pair, sequencing 
strategies assist in these efforts, but often with a tradeoff that large amounts 
of input DNA are required to achieve paired reads from long DNA 
fragments. Thus, resequencing of complex structural variants and de novo 
genome assembly remain a challenge, particularly in DNA-limited 
applications such as cancer genome sequencing. For example, recently 
published de novo assemblies of individual human genomes contain 
millions of contigs and over a hundred thousand scaffolds.  
 
Pacific Biosciences recently demonstrated a new single-molecule 
sequencing technology called strobe sequencing. This technology produces 
strobe reads that consist of multiple subreads from a single long fragment of 
DNA, generalizing the concept of paired reads. Strobe sequencing holds 
promise for resolving complex genomic regions, but realizing this promise 
requires new algorithms for variant detection and de novo assembly. We 
first present an algorithm for structural variation detection from strobe 
sequencing data, and apply our algorithm to simulated strobe read data. 
With 3Kb strobe reads, each consisting of three 200bp subreads with per-
base error rates up to 10%, we achieve a sensitivity of 0.86 in detecting 124 
deletions from the Venter genome. With a lower per-base error rate of 5%, 
we achieve a slightly higher sensitivity of 0.87 and reduce the number of 
false positives by 32%. This demonstrates that our algorithm achieves good 
performance under less than ideal sequencing conditions. Second, we 
describe how to use strobe reads with more than two subreads to resolve 
ambiguities in de novo assembly. Most modern genome assembly programs 
rely on the analysis of an overlap graph to represent alignments between 
reads, with the deBruijn graph being a popular approach for short-read 
assembly. These programs use information from paired reads to join contigs 
after the construction of an overlap graph based on the individual reads. We 
show how to extend this approach to use the multiple constraints provided 
by strobe reads. 
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While personalized genomics has to this point been strongly focused on an 
individual’s germline DNA, there are indications that actionable and highly 
penetrant personal genomics tests will emerge from the fields of virology and 
microbiology. The continued emergence of highly pathogenic viral agents that 
infect large numbers of individuals across broad geographic regions and 
negatively impact the lives and health of entire populations has now more than 
ever driven the need to discover and more fully characterize the genomes of 
viruses present in the environments to which we are exposed daily. Your risk of 
viral infection from common nuisance pathogens like adenovirus, influenza, or 
rotavirus, and more dangerous viruses like the West Nile virus, is a complex 
function of your genome (genetic risk), your level of exposure to pathogens 
(macro-environmental risk), and the state of your immune system with respect 
to its ability to fight infection (micro-environmental risk). To assess the 
feasibility of identifying and tracking changes in the composition of many types 
of viruses in the environment over time, we collected environmental samples 
for DNA sequencing for multiple time points over the course of several months 
from sewage substations and surfaces that would be considered common in a 
workplace, home or school setting, and from the nasal passages of human 
subjects. Using Pacific Biosciences’ single-molecule, real-time (SMRT) DNA 
sequencing technology, we performed direct sequencing of these samples. In 
addition, we carried out targeted amplification of a number of nuisance 
pathogens involved in cold, flu, diarrhea and other infectious diseases. In 
contrast to current DNA sequencing techniques, SMRT sequencing is unique in 
its potential to enable rapid sequencing of the genomes of many viruses 
simultaneously at high fold coverage to identify the entire complement of 
viruses present in a given sample comprising a complex mixture of viral and 
other genomes from a diversity of species. It can also assess differences 
between the genomes of a given species, going beyond simple counts of mutant 
alleles in virus populations to knowing the exact frequency of mutation 
combinations. For the first time, this technology makes it possible to sequence 
pathogens of public health concern from environmental samples sufficiently 
rapidly and economically so that high-throughput sequencing can be employed 
to enable real-time monitoring. This monitoring is not limited to genetic 
variation in environmental viruses - for direct DNA sequencing applications 
SMRT sequencing allows direct detection of modified nucleotides and hence 
epigenetic effects that reflect the environment of the viruses. We present the 
results and analyses of these data and explore the feasibility of a disease 
weather map based on molecular analysis of environmental exposures to disease 
causing agents.  
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visit www.454.com or contact your local Roche 
representative today. 
454, 454 SEQUENCING, GS JUNIOR, and GS FLX 
are trademarks of Roche.
© 2010 Roche Diagnostics. All rights reserved.  
Figure 1: Get the right depth and coverage for your
amplicon project. You can customize your experimental
design to maximize data throughput for optimal sample
coverage per sequencing run. Examples of various 
applications and optimum sample number per run are
shown for the GS Junior System. 
www.454.com 
GS Junior Sequencing System
Roche Diagnostics Corporation
Roche Applied Science
Indianapolis, Indiana
For life science research only. 
Not for use in diagnostic procedures. 
Amplicon Assay
Samples
per Run
HIV Drug Targets (e.g., 16 amplicons covering
5 regions at 1500X [Protease, RT, Integrase,
Envelope V3, gp41 heptad repeats])  
8
Gene Sequencing (e.g., CFTR, 34 amplicons
covering 27 exons at 50X) 
48
HLA Sequencing (e.g., high-resolution 
genotyping at 7 loci) 
16
VDJ Sequencing (e.g., for vaccine response or
minimal residue detection for known clonality) 
8
A NEW Scale of Sequencing  – 
Amplicon Sequencing on Your Benchtop
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VISITOR INFORMATION 
 
EMERGENCY                CSHL                          BANBURY 
Fire (9) 742-3300 (9) 692-4747 
Ambulance (9) 742-3300 (9) 692-4747 
Poison (9) 542-2323 (9) 542-2323 
Police (9) 911 (9) 549-8800 
Safety-Security Extension 8870  
 
Emergency Room 
Huntington Hospital 
270 Park Avenue, Huntington 
631-351-2300 
(1037)  
Dentists 
Dr. William Berg 
Dr. Robert Zeman 
 
631-271-2310 
631-271-8090 
Doctor 
MediCenter 
234 W. Jericho Tpke., Huntington Station 
631-423-5400 
(1034) 
Drugs - 24 hours, 7 days 
Rite-Aid 
391 W. Main Street, Huntington 
631-549-9400 
(1039) 
Free Speed Dial 
Dial the four numbers (****) from any tan house phone to place a 
free call. 
GENERAL INFORMATION 
 
Books, Gifts, Snacks, Clothing, Newspapers 
 BOOKSTORE   367-8837 (hours posted on door) 
 Located in Grace Auditorium, lower level. 
 
Photocopiers, Journals, Periodicals, Books, Newspapers 
 Photocopying – Main Library 
 Hours:  8:00 a.m. – 9:00 p.m. Mon-Fri 
             10:00 a.m. – 6:00 p.m. Saturday 
Helpful tips - Obtain PIN from Meetings & Courses Office  
to enter Library after hours.  See Library staff for photocopier 
code. 
 
Computers, E-mail, Internet access 
 Grace Auditorium 
 Upper level: E-mail only 
 Lower level: Word processing and printing. 
 STMP server address: mail.optonline.net 
 To access your E-mail, you must know the name of your  
 home server.    
 
Dining, Bar 
 Blackford Hall 
  Breakfast  7:30–9:00, Lunch 11:30–1:30, Dinner  5:30–7:00 
  Bar  5:00 p.m. until late  
 Helpful tip - If there is a line at the upper dining area, try the  
 lower dining room 
 
 
 
Messages, Mail, Faxes 
 Message Board, Grace, lower level 
 
Swimming, Tennis, Jogging, Hiking 
June–Sept. Lifeguard on duty at the beach. 12:00 noon–6:00 p.m.  
Two tennis courts open daily. 
 
Russell Fitness Center 
 Dolan Hall, west wing, lower level 
 PIN#:  Press 64490 (then enter #) 
 
Concierge 
 On duty daily at Meetings & Courses Office. 
After hours – From tan house phones, dial x8870 for 
assistance 
  
Pay Phones, House Phones 
Grace, lower level; Cabin Complex; Blackford Hall; Dolan Hall, 
foyer  
 
CSHL’s Green Campus 
 
Cold Spring Harbor Laboratory is pledged to operate in an 
environmentally responsible fashion wherever possible.  In the past, 
we have removed underground oil tanks, remediated asbestos in 
historic buildings, and taken substantial measures to ensure the 
pristine quality of the waters of the harbor. Water used for irrigation 
comes from natural springs and wells on the property itself.  Lawns, 
trees, and planting beds are managed organically whenever possible.  
And trees are planted to replace those felled for construction 
projects.   
 
Two areas in which the Laboratory has focused recent efforts have 
been those of waste management and energy conservation.  The 
Laboratory currently recycles most waste.  Scrap metal, electronics, 
construction debris, batteries, fluorescent light bulbs, toner cartridges, 
and waste oil are all recycled.  For general waste, the Laboratory uses 
a “single stream waste management” system, removing recyclable 
materials and sending the remaining combustible trash to a 
cogeneration plant where it is burned to provide electricity, an 
approach considered among the most energy efficient, while providing 
a high yield of recyclable materials. 
 
Equal attention has been paid to energy conservation.  Most lighting 
fixtures have been replaced with high efficiency fluorescent fixtures, 
and thousands of incandescent bulbs throughout campus have been 
replaced with compact fluorescents.  The Laboratory has also 
embarked on a project that will replace all building management 
systems on campus, reducing heating and cooling costs by as much 
as twenty-five per cent. 
 
Cold Spring Harbor Laboratory continues to explore new ways in 
which we can reduce our environmental footprint, including 
encouraging our visitors and employees to use reusable containers, 
conserve energy, and suggest areas in which the Laboratory’s efforts 
can be improved. This book, for example, is printed on recycled 
paper. 
                       1-800 Access Numbers 
 
 AT&T  9-1-800-321-0288 
 MCI  9-1-800-674-7000 
 
Local Interest 
 Fish Hatchery   631-692-6768 
 Sagamore Hill   516-922-4447 
 Whaling Museum   631-367-3418 
 Heckscher Museum  631-351-3250 
 CSHL DNA Learning  x 5170 
   Center 
 
New York City 
 Helpful tip - 
 Take Syosset Taxi to Syosset Train Station 
 ($8.00 per person, 15 minute ride), then catch Long Island  
 Railroad to Penn Station (33rd Street & 7th Avenue).   
 Train ride about one hour. 
 
   TRANSPORTATION 
Limo, Taxi 
 Syosset Limousine  516-364-9681  (1031) 
 Super Shuttle  800-957-4533  (1033) 
  To head west of CSHL - Syosset train station 
  Syosset Taxi  516-921-2141  (1030) 
 To head east of CSHL - Huntington Village  
  Orange & White Taxi 631-271-3600  (1032) 
Executive Limo  631-696-8000  (1047) 
 
Trains 
 Long Island Rail Road   822-LIRR  
 Schedules available from the Meetings & Courses Office. 
 Amtrak   800-872-7245 
 MetroNorth   800-638-7646 
 New Jersey Transit  201-762-5100 
 
Ferries 
 Bridgeport / Port Jefferson 631-473-0286 (1036) 
 Orient Point/ New London 631-323-2525 (1038) 
 
Car Rentals 
 Avis   631-271-9300 
 Enterprise   631-424-8300 
 Hertz   631-427-6106 
  
Airlines 
 American   800-433-7300 
 America West  800-237-9292 
 British Airways  800-247-9297 
 Continental   800-525-0280 
 Delta   800-221-1212 
 Japan Airlines  800-525-3663 
 Jet Blue   800-538-2583 
 KLM   800-374-7747 
 Lufthansa   800-645-3880 
 Northwest   800-225-2525 
 United   800-241-6522 
 US Airways   800-428-4322 
